CN117545758A - 作为TRPA1抑制剂的咪唑并[4,5-d]哒嗪酮基衍生物 - Google Patents
作为TRPA1抑制剂的咪唑并[4,5-d]哒嗪酮基衍生物 Download PDFInfo
- Publication number
- CN117545758A CN117545758A CN202280025202.4A CN202280025202A CN117545758A CN 117545758 A CN117545758 A CN 117545758A CN 202280025202 A CN202280025202 A CN 202280025202A CN 117545758 A CN117545758 A CN 117545758A
- Authority
- CN
- China
- Prior art keywords
- compound
- compounds
- group
- formula
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 27
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title description 52
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title description 51
- HBKTUIOILXGFSV-UHFFFAOYSA-N C1=NN=CC2=NC(=O)N=C21 Chemical class C1=NN=CC2=NC(=O)N=C21 HBKTUIOILXGFSV-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 238000000034 method Methods 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 150000002367 halogens Chemical class 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 25
- 206010011224 Cough Diseases 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 230000003176 fibrotic effect Effects 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 108020003175 receptors Proteins 0.000 abstract description 7
- 230000001052 transient effect Effects 0.000 abstract description 6
- 102100031366 Ankyrin-1 Human genes 0.000 abstract description 5
- 101710191059 Ankyrin-1 Proteins 0.000 abstract description 5
- 102000008102 Ankyrins Human genes 0.000 abstract description 3
- 108010049777 Ankyrins Proteins 0.000 abstract description 3
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 51
- 239000000203 mixture Substances 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 20
- 210000003494 hepatocyte Anatomy 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 208000029523 Interstitial Lung disease Diseases 0.000 description 19
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 13
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 206010006451 bronchitis Diseases 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- -1 icilin) Chemical class 0.000 description 8
- 210000001853 liver microsome Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000000935 antidepressant agent Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 206010023332 keratitis Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000004957 immunoregulator effect Effects 0.000 description 5
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 201000000306 sarcoidosis Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010009137 Chronic sinusitis Diseases 0.000 description 4
- 208000001528 Coronaviridae Infections Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010039705 Scleritis Diseases 0.000 description 4
- 206010039710 Scleroderma Diseases 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 108060008646 TRPA Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010069351 acute lung injury Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229960001252 methamphetamine Drugs 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 229960001785 mirtazapine Drugs 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 3
- 229960000564 nitrofurantoin Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 3
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- QSGWBYJAYXLQKS-VIFPVBQESA-N (3s)-3-(4-chlorophenyl)-3-hydroxypropanenitrile Chemical compound N#CC[C@H](O)C1=CC=C(Cl)C=C1 QSGWBYJAYXLQKS-VIFPVBQESA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VFHVAQQWARFZLQ-UHFFFAOYSA-N 2,2-dihydroxypropanimidamide Chemical compound CC(O)(O)C(N)=N VFHVAQQWARFZLQ-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- VJWXIRQLLGYIDI-UHFFFAOYSA-N 4,5-dichloro-1h-pyridazin-6-one Chemical compound OC1=NN=CC(Cl)=C1Cl VJWXIRQLLGYIDI-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010001076 Acute sinusitis Diseases 0.000 description 2
- 206010052613 Allergic bronchitis Diseases 0.000 description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 208000035939 Alveolitis allergic Diseases 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- GUKNFPUGQFYKRR-UHFFFAOYSA-N CN1C2=C(C=NNC2=O)N=C1Br Chemical compound CN1C2=C(C=NNC2=O)N=C1Br GUKNFPUGQFYKRR-UHFFFAOYSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- AGWALYOMRYPEHF-UHFFFAOYSA-N ClC1=NNC=CC=C1 Chemical compound ClC1=NNC=CC=C1 AGWALYOMRYPEHF-UHFFFAOYSA-N 0.000 description 2
- JPBAOEFTQBCFII-UHFFFAOYSA-N ClC=C1N=NOC1 Chemical compound ClC=C1N=NOC1 JPBAOEFTQBCFII-UHFFFAOYSA-N 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 208000032972 Conjunctival malignant melanoma Diseases 0.000 description 2
- 206010066384 Conjunctival melanoma Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012441 Dermatitis bullous Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000001708 Dupuytren contracture Diseases 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 2
- 206010015084 Episcleritis Diseases 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- 208000004332 Evans syndrome Diseases 0.000 description 2
- 201000003675 Evans' syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 description 2
- 101710107771 G-protein coupled receptor 84 Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 201000005708 Granuloma Annulare Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 2
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 2
- 206010073310 Occupational exposures Diseases 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000004362 Penile Induration Diseases 0.000 description 2
- 208000020758 Peyronie disease Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 201000002154 Pterygium Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000036428 airway hyperreactivity Effects 0.000 description 2
- 229960004607 alfuzosin Drugs 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229960001164 apremilast Drugs 0.000 description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
- 229960002430 atomoxetine Drugs 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 2
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000029162 bladder disease Diseases 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 201000005668 blepharoconjunctivitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029771 childhood onset asthma Diseases 0.000 description 2
- 239000012069 chiral reagent Substances 0.000 description 2
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 239000012887 cigarette smoke extract Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 239000002817 coal dust Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960002677 darifenacin Drugs 0.000 description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 229960001623 desvenlafaxine Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBIPBYUBAYFWLY-UHFFFAOYSA-N dimethyl 2-bromo-1-methylimidazole-4,5-dicarboxylate Chemical compound BrC=1N(C(=C(N1)C(=O)OC)C(=O)OC)C XBIPBYUBAYFWLY-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 2
- 229950000761 fezolamine Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 102000052408 human TRPA1 Human genes 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 210000002664 langerhans' cell Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960003406 levorphanol Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000002576 malignant conjunctival melanoma Diseases 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- MGAWGVXMGWEQDC-UHFFFAOYSA-N methyl 2-bromo-5-formyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=C(N=C1Br)C=O)C(=O)OC MGAWGVXMGWEQDC-UHFFFAOYSA-N 0.000 description 2
- 239000012022 methylating agents Substances 0.000 description 2
- 229960003404 mexiletine Drugs 0.000 description 2
- 229960003955 mianserin Drugs 0.000 description 2
- 229960001551 mirabegron Drugs 0.000 description 2
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 2
- 229960000805 nalbuphine Drugs 0.000 description 2
- 229960005297 nalmefene Drugs 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 208000030372 neonatal thrombocytopenia Diseases 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960001073 nomifensine Drugs 0.000 description 2
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 description 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000675 occupational exposure Toxicity 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 201000005675 papillary conjunctivitis Diseases 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 2
- 229960005301 pentazocine Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960004953 silodosin Drugs 0.000 description 2
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229960003855 solifenacin Drugs 0.000 description 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960002501 tofisopam Drugs 0.000 description 2
- 229960004045 tolterodine Drugs 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- 239000002341 toxic gas Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 2
- 210000000427 trigeminal ganglion Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960001491 trospium Drugs 0.000 description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 2
- 229960001255 viloxazine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- UEUNDURNLYLSNB-HOTGVXAUSA-N (1S,3S)-3-[2-methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound CC1=NC(=CC=C1O[C@@H]1C[C@H](CCC1)C(=O)O)C=1N=NN(C=1COC(N(CCC)C)=O)C UEUNDURNLYLSNB-HOTGVXAUSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NXUWTKIOMJSLSV-DEEZXRHXSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O NXUWTKIOMJSLSV-DEEZXRHXSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KVXVDYBHRRPRCO-QMMMGPOBSA-N (3S)-3-(4-chlorophenyl)-N',3-dihydroxypropanimidamide Chemical compound ONC(=N)C[C@H](O)C1=CC=C(Cl)C=C1 KVXVDYBHRRPRCO-QMMMGPOBSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- RWBMHWZSWMDMMX-UHFFFAOYSA-N 1,2-oxazol-3-ylhydrazine Chemical compound NNC=1C=CON=1 RWBMHWZSWMDMMX-UHFFFAOYSA-N 0.000 description 1
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 1
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 1
- JYOUFPNYTOFCSJ-UHFFFAOYSA-N 3-(4-chlorophenyl)-3-oxopropanenitrile Chemical compound ClC1=CC=C(C(=O)CC#N)C=C1 JYOUFPNYTOFCSJ-UHFFFAOYSA-N 0.000 description 1
- GTQPEQGDLVSFJO-CXAGYDPISA-N 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-oxolan-3-yl]oxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound CC1=CN=C(S1)C=1C=C(C(=O)N[C@H](C)C=2C=NC(=NC=2)C(F)(F)F)C=C(C=1)O[C@H]1COCC1 GTQPEQGDLVSFJO-CXAGYDPISA-N 0.000 description 1
- CGJHITYLAWJORL-UHFFFAOYSA-N 3-(6-fluoro-1-benzothiophen-2-yl)-3-oxopropanenitrile Chemical compound FC1=CC=C2C=C(C(=O)CC#N)SC2=C1 CGJHITYLAWJORL-UHFFFAOYSA-N 0.000 description 1
- STWVLEKJQQRGMO-GUYCJALGSA-N 3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine Chemical compound ClC1=CC=C(C[C@@H]2N(C[C@@H](OC2)C)C2CCN(CC2)C=2NC(=NN=2)N)C=C1 STWVLEKJQQRGMO-GUYCJALGSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YEZJKOUBKZXNDF-UHFFFAOYSA-N 4,5-diamino-2-(phenylmethoxymethyl)pyridazin-3-one Chemical compound O=C1C(N)=C(N)C=NN1COCC1=CC=CC=C1 YEZJKOUBKZXNDF-UHFFFAOYSA-N 0.000 description 1
- HMPOUYCZGZBFOK-UHFFFAOYSA-N 4,5-dichloro-2-(phenylmethoxymethyl)pyridazin-3-one Chemical compound O=C1C(Cl)=C(Cl)C=NN1COCC1=CC=CC=C1 HMPOUYCZGZBFOK-UHFFFAOYSA-N 0.000 description 1
- LUMJZXGXLLBVFW-UHFFFAOYSA-N 4-amino-5-nitro-2-(phenylmethoxymethyl)pyridazin-3-one Chemical compound O=C1C(N)=C([N+]([O-])=O)C=NN1COCC1=CC=CC=C1 LUMJZXGXLLBVFW-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 229940122849 Autotaxin inhibitor Drugs 0.000 description 1
- 229940125906 BMS-986278 Drugs 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010056695 Bronchial oedema Diseases 0.000 description 1
- KIYDIUCLZDPZMQ-UHFFFAOYSA-N CC(C)(C)OC(CN(C1=O)N=CC2=C1N(C)C=N2)=O Chemical compound CC(C)(C)OC(CN(C1=O)N=CC2=C1N(C)C=N2)=O KIYDIUCLZDPZMQ-UHFFFAOYSA-N 0.000 description 1
- 229940126205 CC-90001 Drugs 0.000 description 1
- BYYDEWGZUNSKGT-UHFFFAOYSA-N CCOC(C(N1C)=C(CO)N=C1Br)=O Chemical compound CCOC(C(N1C)=C(CO)N=C1Br)=O BYYDEWGZUNSKGT-UHFFFAOYSA-N 0.000 description 1
- DBLLWTUFNVMUDR-ZDUSSCGKSA-N CN(C(C=NN(CC1=NC(C[C@@H](C(C=C2)=CC=C2Cl)O)=NO1)C1=O)=C1N1C)C1=O Chemical compound CN(C(C=NN(CC1=NC(C[C@@H](C(C=C2)=CC=C2Cl)O)=NO1)C1=O)=C1N1C)C1=O DBLLWTUFNVMUDR-ZDUSSCGKSA-N 0.000 description 1
- WEMFVDPKBQQCSU-UHFFFAOYSA-N CN(C(C=NN(COCC1=CC=CC=C1)C1=O)=C1N1C)C1=O Chemical compound CN(C(C=NN(COCC1=CC=CC=C1)C1=O)=C1N1C)C1=O WEMFVDPKBQQCSU-UHFFFAOYSA-N 0.000 description 1
- QQMXTQUSJLDHIU-UHFFFAOYSA-N CN(C(C=NNC1=O)=C1N1C)C1=O Chemical compound CN(C(C=NNC1=O)=C1N1C)C1=O QQMXTQUSJLDHIU-UHFFFAOYSA-N 0.000 description 1
- FUIIGSFYZXFWEC-ZDUSSCGKSA-N CN1C(C(N(CC2=NC(C[C@@H](C(C=C3)=CC=C3Br)O)=NO2)N=C2)=O)=C2N=C1 Chemical compound CN1C(C(N(CC2=NC(C[C@@H](C(C=C3)=CC=C3Br)O)=NO2)N=C2)=O)=C2N=C1 FUIIGSFYZXFWEC-ZDUSSCGKSA-N 0.000 description 1
- LGHXAWCYOCUPLJ-UHFFFAOYSA-N CN1C=NC2=C1C(=O)NN=C2.Br Chemical compound CN1C=NC2=C1C(=O)NN=C2.Br LGHXAWCYOCUPLJ-UHFFFAOYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229940125842 Chitinase inhibitor Drugs 0.000 description 1
- BUVPXWRNZBTZCW-VIFPVBQESA-N ClCC1=NC(=NO1)C[C@H](O)C1=CC=C(C=C1)Cl Chemical compound ClCC1=NC(=NO1)C[C@H](O)C1=CC=C(C=C1)Cl BUVPXWRNZBTZCW-VIFPVBQESA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 1
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000027004 Eosinophilic disease Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 1
- 101710142060 Free fatty acid receptor 1 Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 1
- 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 1
- 102000029746 Histidine-tRNA Ligase Human genes 0.000 description 1
- 101710177011 Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 238000013051 Liquid chromatography–high-resolution mass spectrometry Methods 0.000 description 1
- 229940123977 Lysophosphatidic acid receptor antagonist Drugs 0.000 description 1
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 108010083015 MMI-0100 Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 101710166115 Mitogen-activated protein kinase 2 Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- XYQHCMDVGIJOTA-UHFFFAOYSA-N N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyl-1,3-oxazole-5-carboxamide Chemical compound NC(C(C(CC1=CC=CC=C1)NC(=O)C1=C(N=C(O1)C)C1=C(C=CC=C1)F)=O)=O XYQHCMDVGIJOTA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- CZCHTDCFAUAYBM-UHFFFAOYSA-N O=C1NC(C(N(COCC2=CC=CC=C2)N=C2)=O)=C2N1 Chemical compound O=C1NC(C(N(COCC2=CC=CC=C2)N=C2)=O)=C2N1 CZCHTDCFAUAYBM-UHFFFAOYSA-N 0.000 description 1
- 229940125840 OATD-01 Drugs 0.000 description 1
- IHSLLYIFCVKMLK-UHFFFAOYSA-N OC1=C(C=NN(COCC2=CC=CC=C2)C1=O)[N+]([O-])=O Chemical compound OC1=C(C=NN(COCC2=CC=CC=C2)C1=O)[N+]([O-])=O IHSLLYIFCVKMLK-UHFFFAOYSA-N 0.000 description 1
- 206010067472 Organising pneumonia Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010089484 PRM-151 Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- PTKFEDGHUVZLPL-LLUYWJARSA-N Pectenotoxin 2 Chemical compound O[C@@H]1[C@H](C)CCO[C@]1(O)[C@H]1O[C@@H]2/C=C/C(/C)=C/[C@H](C)C[C@](C)(O3)CC[C@@H]3[C@](O3)(O4)CC[C@@]3(C)C[C@@H]4[C@@H](O3)C(=O)C[C@]3(C)[C@@H](O)[C@@H](O3)CC[C@@]3(O3)CCC[C@H]3[C@@H](C)C(=O)O[C@@H]2C1 PTKFEDGHUVZLPL-LLUYWJARSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 101710096715 Probable histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102000027549 TRPC Human genes 0.000 description 1
- 108060008648 TRPC Proteins 0.000 description 1
- 102000027545 TRPM Human genes 0.000 description 1
- 108091008847 TRPM Proteins 0.000 description 1
- 108091008846 TRPML Proteins 0.000 description 1
- 102000027544 TRPML Human genes 0.000 description 1
- 108091008849 TRPN Proteins 0.000 description 1
- 108060009332 TRPP Proteins 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 101710119679 Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- ODGXXYXJORZPHE-ZIAGYGMSSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H]([C@@H](C1)O)F ODGXXYXJORZPHE-ZIAGYGMSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical group OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 229950003210 bradanicline Drugs 0.000 description 1
- OXKRFEWMSWPKKV-RXVVDRJESA-N bradanicline Chemical compound C([C@@H]1N2CCC(CC2)[C@@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-RXVVDRJESA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 229960004587 carisoprodol Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 229960000685 levomilnacipran Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- MLSKXPOBNQFGHW-UHFFFAOYSA-N methoxy(dioxido)borane Chemical compound COB([O-])[O-] MLSKXPOBNQFGHW-UHFFFAOYSA-N 0.000 description 1
- SEHLMRJSQFAPCJ-HNNXBMFYSA-N methyl (2s)-2-[[2-[2,6-difluoro-4-(methylcarbamoyl)phenyl]-7-methylimidazo[1,2-a]pyridin-3-yl]methyl]morpholine-4-carboxylate Chemical compound FC1=CC(C(=O)NC)=CC(F)=C1C1=C(C[C@@H]2OCCN(C2)C(=O)OC)N2C=CC(C)=CC2=N1 SEHLMRJSQFAPCJ-HNNXBMFYSA-N 0.000 description 1
- SQPXPMLXQVWORI-UHFFFAOYSA-N methyl 6-fluoro-1-benzothiophene-2-carboxylate Chemical compound C1=C(F)C=C2SC(C(=O)OC)=CC2=C1 SQPXPMLXQVWORI-UHFFFAOYSA-N 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- UOPFIWYXBIHPIP-SFTDATJTSA-N n-[(1s,2s)-2-amino-1,2-diphenylethyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 UOPFIWYXBIHPIP-SFTDATJTSA-N 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M nitrite group Chemical group N(=O)[O-] IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012725 nonbarbiturate sedative Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229950003481 pamrevlumab Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- PEGQOIGYZLJMIB-UHFFFAOYSA-N setogepram Chemical compound CCCCCC1=CC=CC(CC(O)=O)=C1 PEGQOIGYZLJMIB-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229960004000 talbutal Drugs 0.000 description 1
- BJVVMKUXKQHWJK-UHFFFAOYSA-N talbutal Chemical compound CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O BJVVMKUXKQHWJK-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001166 thiamylal Drugs 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229950004996 tipelukast Drugs 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PRBORDFJHHAISJ-UHFFFAOYSA-N tybamate Chemical compound CCCCNC(=O)OCC(C)(CCC)COC(N)=O PRBORDFJHHAISJ-UHFFFAOYSA-N 0.000 description 1
- 229960002560 tybamate Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- UXDQRXUZPXSLJK-UHFFFAOYSA-N vilazodone Chemical compound C1=CC(C#N)=C[C]2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CN=C21 UXDQRXUZPXSLJK-UHFFFAOYSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 229960002263 vortioxetine Drugs 0.000 description 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- REQQVBGILUTQNN-UHFFFAOYSA-N ziritaxestat Chemical compound CCC=1N=C2C(C)=CC(N3CCN(CC(=O)N4CC(O)C4)CC3)=CN2C=1N(C)C(SC=1C#N)=NC=1C1=CC=C(F)C=C1 REQQVBGILUTQNN-UHFFFAOYSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
本公开内容提供某些咪唑并[4,5‑d]哒嗪酮基衍生物,其为瞬时受体电位锚蛋白1(transient receptor potential ankyrin 1;TRPA1)抑制剂,且因此可用于治疗可通过抑制TRPA1治疗的疾病。本公开内容亦提供含有其的药物组合物及制备所述化合物的方法。A选自由以下组成的组:苯基、噻吩基、苯并噻吩基及苯并呋喃基,且其中A未经取代或经由卤素及C1‑4‑烷基组成的基团R1中一或两个成员取代;或A为E为选自由以下组成的组:
Description
技术领域
本公开内容提供某些咪唑并[4,5-d]哒嗪酮基衍生物,其为瞬时受体电位锚蛋白1(TRPA1)抑制剂且因此可用于治疗可通过抑制TRPA1治疗的疾病。亦提供含有其的药物组合物及制备所述化合物的方法。
背景技术
瞬时受体电位信道(TRP信道)为主要位于许多哺乳动物细胞类型的质膜上的一组电压闸控离子信道。存在大约30种结构相关的TRP信道,其分为以下群组:TRPA、TRPC、TRPM、TRPML、TRPN、TRPP及TRPV。瞬时受体电位阳离子通道亚家族A成员1(TRPA1)(也称为瞬时受体电位锚蛋白1)为TRPA基因亚家族的唯一成员。在结构上,TRPA信道的特征在于多个N-末端锚蛋白重复(在人类TRPA1的N-末端中约14个),其产生锚蛋白名称的“A”(Montell,2005)。
TRPA1高度表达于服务于皮肤及肺二者的背根及结节神经节中的感觉神经元的质膜中、以及小肠、结肠、胰脏、骨骼肌、心脏、脑、膀胱及淋巴球中(https://www.proteinatlas.org/)以及人类肺纤维母细胞中。
TRPA1是最著名的环境刺激物的传感器,引起诸如疼痛、寒冷及瘙痒等体感觉样式。TRPA1由许多反应性、亲电刺激物(例如,异硫氰酸烯丙酯、活性含氧物)以及非反应性化合物(例如冰素(icilin))激活,其涉及与气喘、慢性肺阻塞性疾病(COPD)、特发性肺纤维化(IPF)或病毒后咳嗽相关的咳嗽或慢性特发性咳嗽以及敏感患者的咳嗽。(Song及Chang,2015;Grace及Belvisi,2011)。TRPA1抑制剂可用于治疗IPF,其中基于显示咳嗽引起TGF-β升高的研究,由于咳嗽与肺损伤之间的联系,咳嗽在IPF中非常普遍(Xie等人,2009;Froese等人,2016;Tschumperlin等人,2003;Yamamoto等人,2002;Ahamed等人,2008)。SARS-Cov-2感染导致的急性肺损伤至少部分地经由活性含氧物(ROS)介导。ROS为TRPA1的直接活化剂。此外,经由食用辛辣食物使TRPA1去敏被认为调节Nrf2路径并减少氧化压力(Bousquet等人,2020;Bousquet等人,2021)。因此,TRPA1抑制剂在治疗新冠病毒(Covid-19)/SARS-Cov-2引起的肺损伤方面具有潜力。TRPA1拮抗剂抑制由咳嗽触发因素(例如香烟烟雾提取物(CSE)氧化应激、发炎介质释放及抗氧化基因表达下调)触发的钙信号传导(Lin等人,2015;Wang等人,2019)。TRPA1拮抗剂在异位性皮肤炎(Oh等人,2013;Wilson等人,2013)、接触性皮肤炎(Liu等人,2013)、牛皮癣相关的瘙痒(Wilson等人,2013)及IL-31依赖性瘙痒(Cevikbas等人,2014)的研究中是有效的。人类TRPA1功能获得与家族性阵发性疼痛综合征相关联(Kremeyer等人,2010)。TRPA1拮抗剂在偏头痛相关的触摸痛的行为模型中是有效的(Edelmayer等人,2012)。与TRPA1在支配健康牙齿的三叉神经节中的表达相比,TRPA1在支配受损牙齿的三叉神经节中的表达选择性地增加(Haas等人,2011)。已知几种麻醉剂为TRPA1激动剂,包括异氟醚(Matta等人,2008),这是TRPA1抑制剂缓解术后疼痛提供理论基础。TRPA1剔除的小鼠及利用TRPA1拮抗剂治疗的野生型小鼠显示抗焦虑及抗抑郁样表型(de Moura等人,2014)。基于显示AMPK与TRPA1之间反向调节的机制联系的研究,TRPA1抑制剂预期在治疗糖尿病神经病变中具有益处(Hiyama等人,2018;Koivisto及Pertovaara,2013;Wang等人,2018)。TRPA1剔除小鼠与野生型小鼠相比展现较小的心肌梗塞大小(Conklin等人,2019)。TRPA1剔除及药理学介入抑制小鼠中TNBS引发的结肠炎(Engel等人,2011)。在小鼠脑缺血模型中,TRPA1剔除及TRPA1拮抗剂减少髓鞘损伤(Hamilton等人,2016)。在痛风的尿酸单钠小鼠模型中,尿酸盐晶体及关节发炎在TRPA1剔除小鼠中减少(Moilanen等人,2015)。大鼠中的TRPA1缺失在急性痛风发作的大鼠模型中改善关节发炎及痛觉过敏(Trevisan等人,2014)。TRPA1的激活引发在骨关节炎软骨细胞中引发发炎反应(Nummenmaa等人,2016)。TRPA1抑制及基因缺失减少骨关节炎小鼠软骨细胞及鼠类软骨中的发炎介质(Nummenmaa等人,2016)。最后,TRPA1剔除小鼠在MIA诱发的膝肿胀模型中展现骨关节炎肢体的负重改良(Horvath等人,2016)。TRPA1差异表达于膀胱出口阻塞的大鼠的膀胱上皮(Du等人,2007)及患者的膀胱上皮(Du等人,2008)中。TRPA1受体调节减弱脊髓损伤的大鼠模型中的膀胱过度活动(Andrade等人,2011)且鞘内施用TRPA1拮抗剂减弱患有反射过度排尿的大鼠中环磷酰胺引发的膀胱炎(Chen等人,2016)。
因此期望提供强效TRPA1抑制剂。
各种结构类型的TRPA1抑制剂综述于S.Skerratt,Progress in MedicinalChemistry,2017,第56卷,81-115及D.Preti、G.Saponaro、A.Szallasi,Pharm.Pat.Anal.(2015)4(2),75-94及H.Chen,Transient receptor potential ankyrin 1(TRPA1)antagonists:a patent review(2015-2019),Expert Opin Ther Pat.,2020中。
WO2017/060488公开为TRPA1拮抗剂的化合物,其具有以下结构通式
其中在钙通量分析中公开实施例53、72、73、86及90的TRPA1活性具有小于100nM的IC50。
L.Schenkel等人,J.Med.Chem.2016,59,2794-2809公开基于喹唑啉酮的TRPA1拮抗剂,其包括以下结构通式的化合物
其中化合物31(其中R为OH)在FLIPR分析中公开具有IC50 58nM的拮抗TRPA1活性且在人类肝微粒体中具有<14μL/min/kg的固有清除率。
具体实施方式
本发明公开新颖咪唑并[4,5-d]哒嗪酮基衍生物,其为瞬时受体电位锚蛋白1(TRPA1)的抑制剂,具有适当药理学及药物动力学性质,使其能够作为药剂用于治疗可通过抑制TRPA1治疗的病况和/或疾病。
本发明化合物可提供若干优点,例如增强的功效、高代谢和/或化学稳定性、高选择性、安全性及耐受性、增强的溶解性、增强的渗透性、期望的血浆蛋白结合、增强的生物利用度、适宜药物动力学曲线及形成稳定盐的可能性。
本发明化合物
本发明提供咪唑并[4,5-d]哒嗪酮基衍生物,其为TRPA1的令人惊讶的强效抑制剂(分析A),其特征进一步在于
-在人类肝微粒体中经改良的稳定性(分析B)
-在人类肝细胞中经改良的稳定性(分析C)。
本发明化合物在结构上不同于WO2017/060488中的实施例53、72、73、86及90以及L.Schenkel等人,J.Med.Chem.2016,59,2794-2809中的实施例31,这是因为其含有经取代咪唑并[4,5-d]哒嗪酮基核心以及毗邻第二脂肪族醇的取代基。所述结构差异意外地导致以下的有利组合:(i)TRPA1的抑制,(ii)在人类肝微粒体中的稳定性,及(iii)在人类肝细胞中的稳定性。
在人类肝微粒体中的稳定性是指在选择和/或设计具有有利药物动力学性质的药物作为第一筛选步骤的情景中化合物对生物转化的敏感性。许多药物的主要代谢部位为肝脏。人类肝微粒体含有细胞色素P450(CYP),且因此代表用于研究体外I期药物代谢的模型系统。在人类肝微粒体中的增强稳定性与若干优点相关联,包括增加的生物利用度及足够半衰期,此可使能够降低及减少患者的频繁给药。因此,在人类肝微粒体中的增强稳定性是欲用于药物的化合物的有利特征。因此,除能够抑制TRPA1以外,本发明化合物预期具有有利的体内清除率且因此在人类中的期望作用持续时间。
在人类肝细胞中的稳定性是指在选择和/或设计具有有利药物动力学性质的药物的情景中化合物对生物转化的敏感性。许多药物的主要代谢部位为肝脏。人类肝细胞含有细胞色素P450(CYP)及其他药物代谢酶,且因此代表用于研究体外药物代谢的模型系统。(重要的是,与肝微粒体分析相比,肝细胞分析亦涵盖II期生物转化以及肝特异性运输蛋白介导的过程,且因此代表用于药物代谢研究的更完整系统)。在人类肝细胞中的增强稳定性与若干优点相关联,包括增加的生物利用度及足够半衰期,此可使能够降低及减少患者的频繁给药。因此,在人类肝细胞中的增强稳定性为欲用于药物的化合物的有利特征。
本发明提供式(I)的新颖化合物
其中
A选自由以下组成的组:苯基、噻吩基、苯并噻吩基及苯并呋喃基,且其中A未经取代或经由卤素及C1-4-烷基组成的基团R1的一或两个成员取代;
或A为
E为选自由以下组成的组:
及/>
本发明另一实施方案涉及式(I)化合物,其中A选自由以下组成的组:苯基、噻吩基、苯并噻吩基及苯并呋喃基,且其中A未经取代或经由Br、Cl、F及H3C组成的基团R1的一或两个成员取代;
或A为
且取代基E如前述实施方案中所定义。
本发明另一实施方案涉及式(I)化合物,其中A选自由以下组成的组:苯基、苯并噻吩基及苯并呋喃基,且其中A未经取代或经由卤素及C1-4-烷基组成的基团R1的一或两个成员取代;
或A为
且取代基E为如前述实施方案中的任一者中所定义。
本发明另一实施方案涉及式(I)化合物,其中A选自由以下组成的组:苯基、苯并噻吩基及苯并呋喃基,且其中A未经取代或经由Br、Cl、F及H3C组成的基团R1的一或两个成员取代;
或A为
且取代基E为如前述实施方案中的任一者中所定义。
本发明另一实施方案涉及式(I)化合物,其中A为选自由以下组成的组:
及/>
且其中A未经取代或经基团R1的一或两个成员取代,
或
A为
且取代基E及R1为如前述实施方案中的任一者中所定义。
本发明另一实施方案涉及式(I)化合物,其中
A为选自由以下组成的组:
及
且取代基E为如前述实施方案中的任一者中所定义。
本发明另一实施方案涉及式(I)化合物,其中E为
且取代基A为如前述实施方案中的任一者中所定义。
本发明另一实施方案涉及式(I)化合物,其中E为
且取代基A为如前述实施方案中的任一者中所定义。
尤其优选者为选自由以下组成的组的式(I)化合物
及
所用术语及定义
本文中未明确定义的术语应给予本领域技术人员根据公开内容及上下文会给予的含义。然而,除非指定相反含义,否则如说明书中所用的以下术语具有所指示含义且遵守以下惯例。
在下文所定义的基团(group)、基团(radical)或部分中,碳原子数通常在基团之前指明,例如C1-6烷基意指具有1至6个碳原子的烷基。通常在诸如HO、H2N、(O)S、(O)2S、NC(氰基)、HOOC、F3C或诸如此类的基团中,本领域技术人员可自基团本身的自由价看出至分子的基团附着点。对于包含两个或以上子基团的组合基团,最后命名的子基团为基团附接点,例如取代基“芳基-C1-3-烷基-”意指键合至C1-3-烷基-基团的芳基,该C1-3-烷基-基团键合至核心或该取代基所附接的基团。
在本发明化合物以化学名称形式描述或描述为化学式的情形中,在出现任何不一致时,以化学式为准。可在子式中使用星号来指示如所定义连接至核心分子的键。
取代基的原子编号始于距离核心或取代基所附接的基团最近的原子。
举例而言,术语“3-羧基丙基-基团”代表以下取代基:
其中羧基附接至丙基的第三个碳原子。术语“1-甲基丙基-”、“2,2-二甲基丙基-”或“环丙基甲基-”基团代表以下基团:
可在子式中使用星号来指示如所定义连接至核心分子的键。
单独或与另一基团组合的术语“C1-n-烷基”(其中n为选自2、3、4或5的整数)表示具有1至n个C原子的非环状、饱和、具支链或直链烃基团。举例而言,术语C1-5-烷基包括基团H3C-、H3C-CH2-、H3C-CH2-CH2-、H3C-CH(CH3)-、H3C-CH2-CH2-CH2-、H3C-CH2-CH(CH3)-、H3C-CH(CH3)-CH2-、H3C-C(CH3)2-、H3C-CH2-CH2-CH2-CH2-、H3C-CH2-CH2-CH(CH3)-、H3C-CH2-CH(CH3)-CH2-、H3C-CH(CH3)-CH2-CH2-、H3C-CH2-C(CH3)2-、H3C-C(CH3)2-CH2-、H3C-CH(CH3)-CH(CH3)-及H3C-CH2-CH(CH2CH3)-。
添加至“烷基”、“亚烷基”或“环烷基”(饱和或不饱和)的术语“氟”是指其中一个或多个氢原子经氟原子取代的烷基或环烷基。实例包括(但不限于):H2FC-、HF2C-及F3C-。
术语苯基是指以下环的基团
术语噻吩基是指以下环的基团
术语苯并呋喃基是指以下环的基团
术语苯并噻吩基是指以下环的基团
术语咪唑并[4,5-d]哒嗪酮基是指以下二环核心的基团
如本文所用,术语“经取代”意指所指定原子上的任一个或多个氢经来自所指示基团的选择置换,前提为不超过所指示原子的正常化合价,且该取代产生稳定化合物。
除非明确指示,否则在整个说明书及随附权利要求书中,给定化学式或名称应涵盖互变异构体及所有立体、光学及几何异构体(例如镜像异构体、非镜像异构体、E/Z异构体等)及其外消旋体,以及不同比例的单独镜像异构体的混合物、非镜像异构体的混合物或前述任一形式的混合物(倘若存在所述异构体及镜像异构体),以及其盐(包括药学上可接受的盐)及其溶剂合物,例如水合物,包括游离化合物的溶剂合物或该化合物的盐的溶剂合物。
一般而言,实质上纯的立体异构体可根据本领域技术人员已知的合成原理获得,例如通过分离相应混合物、通过使用立体化学纯的起始材料和/或通过立体选择性合成。本领域已知如何制备光学活性形式,例如通过拆分外消旋形式或通过例如自光学活性起始材料开始来合成和/或通过使用手性试剂。
本发明镜像异构纯化合物或中间体可经由不对称合成来制备,例如通过制备及随后分离可通过已知方法(例如通过色谱分离或晶体)分离的适当非镜像异构化合物或中间体和/或通过手性试剂,例如手性起始材料、手性触媒或手性助剂。
此外,本领域技术人员已知如何自相应外消旋混合物制备镜像异构纯化合物,例如通过相应外消旋混合物在手性固定相上的色谱分离;或通过外消旋混合物使用适当拆分剂的拆分,例如借助外消旋化合物与光学活性酸或碱的非镜像异构盐形成、盐的随后拆分及自盐释放期望化合物;或通过利用光学活性手性辅助试剂衍生相应外消旋化合物、随后非镜像异构体分离及去除手性辅助基团;或通过外消旋体的动力学拆分(例如通过酶拆分);通过在适宜条件下自镜像异构晶体的聚集体进行镜像选择性晶体;或通过在光学活性手性辅助剂的存在下自适宜溶剂(部分)晶体。
本文采用词组“药学上可接受”以指在合理的医学判断范围内适于使用而没有过度毒性、刺激、过敏反应或其他问题或并发症并与合理的收益/风险比相称的那些化合物、材料、组合物和/或剂型。
如本文所用,“药学上可接受的盐”是指所公开化合物的衍生物,其中母体化合物与酸或碱形成盐或络合物。
与含有碱性部分的母体化合物形成药学上可接受的盐的酸的实施例包括无机或有机酸,例如苯磺酸、苯甲酸、柠檬酸、乙磺酸、富马酸、龙胆酸、氢溴酸、盐酸、马来酸、苹果酸、丙二酸、苦杏仁酸、甲磺酸、4-甲基-苯磺酸、磷酸、水杨酸、琥珀酸、硫酸及酒石酸。
与含有酸性部分的母体化合物形成药学上可接受的盐的阳离子及碱的例子包括Na+、K+、Ca2+、Mg2+、NH4 +、L-精氨酸、2,2’-亚氨基双乙醇、L-赖氨酸、N-甲基-D-葡萄糖胺或三(羟基甲基)-氨基甲烷。本发明的药学上可接受的盐可通过常规化学方法自含有碱性或酸性部分的母体化合物合成。通常,所述盐可通过使所述化合物的游离酸或碱形式与足量的适当碱或酸于水或有机稀释剂(例如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈(或其混合物))中进行反应来制得。
除上述的那些以外可例如用于纯化或分离本发明化合物的其他酸的盐(例如三氟乙酸盐)亦构成本发明的一部分。
生物学分析
TRPA1活性的评估
分析A:TRPA1分析
本发明化合物的活性可使用以下体外TRPA1细胞分析来证实:
方法:
使用过表达人类TRPA1离子通道的人类HEK293细胞系(Perkin Elmer,产品号AX-004-PCL)作为化合物效能及功效的测试系统。化合物活性通过在FLIPRtetra系统(Molecular Devices)中测量化合物对AITC(异硫氰酸烯丙酯)促效作用诱导的细胞内钙浓度的效应来确定。
细胞培养:
细胞系在冷冻小瓶中呈冷冻细胞获得并在-150℃下储存直至使用。
使细胞在培养基(具有10% FCS及0.4mg/ML建那霉素(Geneticin)的MEM/EBSS培养基)中生长。重要的是密度不超过90%铺满。为进行传代培养,通过Versene将细胞自烧瓶分离。在分析前一天,将细胞分离,用培养基(具有10% FCS的MEM/EBSS培养基)洗涤两次,并将20000个细胞以20μl/孔接种于来自Corning的聚D-赖氨酸生物涂布的384孔板(黑色,透明底,Cat.356697)。在分析之前,将板在37℃/5% CO2下培育24小时。
化合物制备
将测试化合物以10mM的浓度溶解于100% DMSO中,且在第一步骤中于DMSO中稀释至5mM的浓度,随后在100% DMSO中进行连续稀释步骤。稀释因子及稀释步骤的数量可根据需要而变。通常以1:5稀释度制备8个不同浓度,使用HBSS/HEPES缓冲液(来自Gibco的1xHEPES,Cat.14065,来自SIGMA的20mM HEPES,Cat.83264,来自Invitrogen的0.1% BSACat.11926,pH 7.4)实施物质的其他中间稀释度(1:20)。
FLIPR分析:
在分析日,细胞用分析缓冲液洗涤3次,洗涤后20μL缓冲液留在孔中。将于HBSS/HEPES中的10μL Ca6试剂盒(Cat.R8191 MolecularDevices)加载缓冲液添加至细胞中,并将板在37℃/5% CO2下加盖培育120分钟。将来自中间稀释板的于HBSS/HEPES缓冲液/5%DMSO中的10μL化合物或对照小心地添加至孔中。在FLIPRtetra装置上读取发光(指示钙流入或释放)达10分钟,以监测化合物诱导的效应(例如促效作用)。最后,将溶于HBSS/HEPES缓冲液/0.05% DMSO中的10μL激动剂AITC 50μM(最终浓度为10μM)添加至孔,随后在FLIPRtetra装置上额外读取10分钟。使用AITC添加后的信号曲线下面积(AUC)用于IC50/%抑制计算。
数据评估及计算:
每一分析微量滴定板均含有具有媒剂(1% DMSO)对照代替化合物的孔作为用于AITC诱导发光的对照(100%CTL;高对照)以及具有媒剂对照而无AITC的孔作为用于非特异性发光变化的对照(0%CTL;低对照)。
数据分析为通过计算个别孔的信号曲线下面积来实施。基于此值,使用MegaLab软件(内部开发)计算针对每一物质浓度测量的%值(AUC(试样)-AUC(低))*100/(AUC(高)-AUC(低))。IC50值为使用MegaLab软件自%对照值计算。计算:[y=(a-d)/(1+(x/c)^b)+d],a=低值,d=高值;x=浓度M;c=IC50 M;b=希尔(hill)斜率;y=%ctrl
表1:分析A中所获得本发明化合物的生物数据
实施例 | hTRPA1 IC50[nM] |
1 | 22 |
2 | 47 |
3 | 147 |
4 | 158 |
5 | 60 |
6 | 96 |
7 | 204 |
8 | 41 |
9 | 9 |
10 | 13 |
11 | 19 |
12 | 24 |
13 | 9 |
14 | 19 |
15 | 47 |
16 | 79 |
表2:分析A中所获得的背景技术化合物(WO2017/060488中的实施例53、72、73、86、90)的生物数据.
WO2017/060488中的实施例 | hTRPA1 IC50[nM] |
53 | 36 |
72 | 14 |
73 | 28 |
86 | 67 |
90 | 41 |
表3:分析A中所获得的背景技术化合物(L.Schenkel等人,J.Med.Chem.2016,59,2794-2809中的实施例31)的生物数据.
评估微粒体清除率
分析B:微粒体清除率:
测试化合物的代谢降解为在37℃下利用汇集的肝微粒体进行分析。每时间点的100μl最终培育体积含有在RT下pH 7.6的TRIS缓冲液(0.1M)、氯化镁(5mM)、微粒体蛋白质(1mg/ml)及最终浓度为1μM的测试化合物。
在37℃下的短预培育时期后,反应通过添加经还原形式的β-烟碱酰胺腺嘌呤二核苷酸磷酸(NADPH,1mM)起始,并在不同时间点(0、5、15、30、60min)后通过将等份试样转移至溶剂中来终止。另外,在没有NADPH的培育中监测NADPH非依赖性降解,在最后一个时间点终止。NADPH独立培育后的[%]剩余测试化合物由参数c(对照)(代谢稳定性)反映。将骤冷的培育物通过离心(10000g,5min)制成丸粒。
通过LC-MS/MS分析上清液等份试样的母体化合物的量。半衰期(t1/2INVITRO)为通过浓度-时间曲线的半对数曲线图的斜率确定。
固有清除率(CL_INTRINSIC)为通过考虑培育中蛋白质的量来计算:
CL_INTRINSIC[μl/min/mg蛋白质]=(Ln 2/(半衰期[min]*蛋白质含量[mg/ml]))*1000
CL_INTRINSIC_INVIVO[ml/min/kg]=(CL_INTRINSIC[μL/min/mg蛋白质]x MPPGL[mg蛋白质/g肝]x肝因子[g/kg体重])/1000
Qh[%]=(CL[ml/min/kg]/肝血流量[ml/min/kg])
肝细胞性,人类:120x10e6个细胞/g肝
肝因子,人类:25.7g/kg体重
血流量,人类:21ml/(min x kg)
表4:分析B中所获得本发明化合物的生物数据
实施例 | 人类LM[%Qh] |
1 | <23 |
2 | <23 |
3 | <23 |
4 | <23 |
5 | <23 |
6 | <23 |
7 | <23 |
8 | <23 |
9 | 41 |
10 | <23 |
11 | 30 |
12 | 31 |
13 | 36 |
14 | <23 |
15 | <23 |
16 | <23 |
表5:分析B中所获得的背景技术化合物(WO2017/060488中的实施例53、72、73、86、90)的生物数据.
WO2017/060488中的实施例 | 人类LM[%Qh] |
53 | <23 |
72 | 30 |
73 | 38 |
86 | <23 |
90 | 39 |
表6:分析B中所获得的背景技术化合物(L.Schenkel等人,J.Med.Chem.2016,59,2794-2809中的实施例31)的生物数据.
评估肝细胞清除率
分析C:肝细胞清除率
在肝细胞悬浮液中分析测试化合物的代谢降解。将肝细胞(冷冻保存)在含有5%物种血清的达尔伯克改良伊格尔培养基(Dulbecco′s modified eagle medium)(补充有3.5μg升糖素/500mL、2.5mg胰岛素/500mL及3.75mg氢化可的松/500mL)。
在培育器(37℃,10% CO2)中30min预培育之后,将5μl测试化合物溶液(80μM;自2mM于DMSO中的原液利用培养基1:25稀释)添加至395μl肝细胞悬浮液(取决于物种,细胞密度在0.25-5百万个细胞/mL的范围内,通常1百万个细胞/mL;测试化合物的最终浓度为1μM,最终DMSO浓度为0.05%)。
将细胞培育六小时(培育器、定轨振荡器)并在0、0.5、1、2、4及6小时时采集试样(25μl)。将试样转移至乙腈中并通过离心(5min)制成丸粒。将上清液转移至新的96深孔板,在氮下蒸发并重新悬浮。
通过HPLC-MS/MS分析母体化合物的减少。
CLint为如下计算:CL_INTRINSIC=剂量/AUC=(C0/CD)/(AUD+clast/k)×1000/60。C0:培育中的初始浓度[μM],CD:活细胞的细胞密度[10e6个细胞/mL],AUD:数据下面积[μM x h],clast:最后一个数据点的浓度[μM],k:母体减少的回归线斜率[h-1]。
所计算的体外肝固有清除率可放大至固有体内肝清除率并通过使用肝脏模型(充分搅拌模型)用于预测肝体内血液清除率(CL)。
CL_INTRINSIC_INVIVO[ml/min/kg]=(CL_INTRINSIC[μL/min/10e6个细胞]x肝细胞性[10e6个细胞/g肝]x肝因子[g/kg体重])/1000
CL[ml/min/kg]=CL_INTRINSIC_INVIVO[ml/min/kg]x肝血流量[ml/min/kg]/(CL_INTRINSIC_INVIVO[ml/min/kg]+肝血流量[ml/min/kg])
Qh[%]=(CL[ml/min/kg]/肝血流量[ml/min/kg])
肝细胞性,人类:120x10e6个细胞/g肝
肝因子,人类:25.7g/kg体重
血流量,人类:21ml/(min x kg)
表7:分析C中所获得本发明化合物的生物数据
实施例 | 人类肝细胞[%Qh] |
1 | 10 |
2 | 14 |
3 | 13 |
4 | 9 |
5 | 23 |
6 | 9 |
7 | 9 |
8 | 39 |
9 | 43 |
10 | 29 |
11 | 35 |
12 | 42 |
14 | 43 |
15 | 12 |
16 | 14 |
表8:分析C中所获得的背景技术化合物(WO2017/060488中的实施例53、72、73、86、90)的生物数据.
WO2017/060488中的实施例 | 人类肝细胞[%Qh] |
53 | 25 |
72 | 50 |
73 | 36 |
86 | 12 |
90 | 61 |
表9:分析C中所获得的背景技术化合物(L.Schenkel等人,J.Med.Chem.2016,59,2794-2809中的实施例31)的生物数据.
评估渗透性
将Caco-2细胞(1-2×105个细胞/1cm2面积)接种于过滤器插入物(Costartranswell聚碳酸酯或PET过滤器,0.4μm孔径)并培养(DMEM)10至25天。
将化合物溶解于适当溶剂(如DMSO,1-20mM原液)中。原液用HTP-4缓冲液(128.13mM NaCl、5.36mM KCl、1mM MgSO4、1.8mM CaCl2、4.17mM NaHCO3、1.19mM Na2HPO4 x7H2O、0.41mM NaH2PO4xH2O、15mM HEPES、20mM葡萄糖、0.25% BSA,pH 7.2)稀释,以制备输送溶液(0.1-300μM化合物,最终DMSO<=0.5%)。输送溶液(TL)分别施加至顶端或底侧供给侧用于测量A-B或B-A渗透性(3个过滤器重复)。试样为在实验开始及结束时自供给处收集且亦自接收侧以不同时间间隔收集长达2小时,用于通过HPLC-MS/MS或闪烁计数进行浓度测量。所采样的接收体积由新鲜接收溶液取代。
评估血浆蛋白结合
使用此平衡透析(ED)技术测定测试化合物与血浆蛋白的体外分数结合的近似值。使用Dianorm铁氟龙(Teflon)透析细胞(micro 0.2)。每一单元由供体及受体腔室组成,所述腔室由具有5kDa分子量截止值的超薄半渗透膜隔开。每一测试化合物的原液为在DMSO中以1mM制备并稀释至1.0μM的最终浓度。随后的透析溶液为于来自雄性及雌性供体的汇集人类或大鼠血浆(具有NaEDTA)中制备。将200μL透析缓冲液(100mM磷酸钾,pH 7.4)的等份试样分配于缓冲液腔室中。将200μL测试化合物透析溶液的等份试样分配于血浆腔室中。培育在旋转下在37℃下实施2小时。
在透析时期结束时,将透析液转移至反应管中。缓冲液馏分的管中含有0.2mLACN/水(80/20)。将25μL血浆透析液的等份试样转移至深孔板中并与25μL ACN/水(80/20)、25μL缓冲液、25μL校正溶液及25μL内标准品溶液混合。通过添加200μL ACN实施蛋白质沉淀。将50μL缓冲液透析液的等份试样转移至深孔板中并与25μL空白血浆、25μL内标准品溶液及200μL ACN混合。试样在HPLC-MS/MS系统上进行测量并利用Analyst软件进行评估。结合百分比为利用以下方程式计算:结合%=(血浆浓度-缓冲液浓度/血浆浓度)×100。
评估溶解性
饱和溶液为在孔板(格式取决于机器人)中通过将适当体积的所选水性介质(通常在0.25-1.5ml范围内)添加至每一孔来制备,每一孔中含有已知数量的固体原料药(通常在0.5-5.0mg范围内)。将孔振荡或搅拌预定时间段(通常在2-24h的范围内)且然后使用适当过滤膜(通常具有0.45μm孔径的PTFE过滤器)过滤。通过丢弃最初几滴滤液来避免过滤器吸收。所溶解原料药的量为通过UV光谱测定。此外,使用玻璃电极pH计测量饱和水溶液的pH。
评估药物动力学特征
将测试化合物经静脉内或经口施用给各别测试物种。在施加测试化合物后的几个时间点采集血液试样,抗凝并离心。
对血浆试样中分析物(即,所施用化合物和/或代谢物)的浓度进行定量。PK参数为使用非房室法计算。AUC及Cmax正规化至1μmol/kg的剂量。
体外评估在人类肝细胞中的代谢
使用悬浮液中的原代人类肝细胞研究测试化合物的代谢途径。自冷冻保存恢复后,将人类肝细胞在含有5%人类血清且补充有3.5μg升糖素/500ml、2.5mg胰岛素/500ml及3.75mg氢化可的松/500ml的达尔伯克改良伊格尔培养基中培育。
在细胞培养培育器(37℃,10% CO2)中30min预培育之后,将测试化合物溶液掺加于肝细胞悬浮液中以获得1.0*106至4.0*106个细胞/ml的最终细胞密度(取决于利用原代人类肝细胞观察的化合物的代谢转换速率)、10μM的最终测试化合物浓度及0.05%的最终DMSO浓度。
将细胞在细胞培养培育器中在水平振荡器上培育六小时,并在0、0.5、1、2、4或6小时后自培育取试样,此取决于代谢转换速率。试样用乙腈骤冷并通过离心制成丸粒。将上清液转移至96深孔板,在氮下蒸发并重新悬浮,然后通过液相色谱-高分辨率质谱进行生物分析以鉴别推定代谢物。
结构基于傅里叶变换(Fourier-Transform)-MSn数据临时指派。代谢物报告为人类肝细胞培育中母体的百分比,其中临限值≥4%。
治疗方法
本发明涉及通式1的化合物,其可用于预防和/或治疗与TRPA1活性相关或通过TRPA1活性调节的疾病和/或病况,包括(但不限于)治疗和/或预防纤维变性疾病、发炎及免疫调节病症、呼吸道或胃肠道疾病或不适、眼科疾病、关节的炎性疾病及鼻咽、眼睛及皮肤的炎性疾病及疼痛及神经病症。所述病症、疾病及病苦包括咳嗽、特发性肺纤维化、其他肺间质性疾病及其他纤维变性、气喘或过敏性疾病、嗜酸性球疾病、慢性阻塞性肺病、以及发炎及免疫调节病症(例如类风湿性关节炎及动脉粥样硬化)、以及疼痛及神经病症(例如急性疼痛、手术疼痛、慢性疼痛及抑郁症)及膀胱病症。
通式1的化合物可用于预防和/或治疗以下各项:
(1)咳嗽,例如慢性特发性咳嗽或慢性难治性咳嗽、与气喘、COPD、肺癌、病毒感染后及特发性肺纤维化及其他肺间质性疾病相关的咳嗽。
(2)肺纤维变性疾病,例如肺炎或与胶原变性相关之间质性肺炎,例如红斑狼疮、全身性硬皮症、类风湿性关节炎、多发性肌炎及皮肌炎、特发性间质性肺炎(例如特发性肺纤维化(IPF))、非特异性间质性肺炎、呼吸性细支气管炎伴间质性肺病、脱屑性间质性肺炎、隐源性机化性肺炎、急性间质性肺炎及淋巴球性间质性肺炎、淋巴管平滑肌瘤病、肺泡蛋白质沉着症、兰格罕细胞组织球增生症(Langerhan’s cell histiocytosis)、胸膜实质弹性纤维增生、已知病因之间质性肺病,例如由于职业暴露导致之间质性肺炎,例如石棉肺、硅肺病、矿工肺(煤尘)、农夫肺(干草及霉菌)、鸽友肺(鸟类)或其他职业性空中浮游触发因素,例如金属粉尘或分枝杆菌,或由治疗(例如辐射、甲胺喋呤(methotrexate)、胺碘酮(amiodarone)、呋喃妥因(nitrofurantoin)或化学治疗剂)导致之间质性肺炎,或肉芽肿疾病,例如肉芽肿性多发性血管炎、查-施二氏综合征(Churg-Strauss syndrome)、类肉瘤病、过敏性肺炎、或由不同病因造成之间质性肺炎(例如误吸、吸入有毒气体、蒸气,支气管炎或肺炎或由心脏衰竭、X-射线、辐射、化学疗法、M.boeck症或类肉瘤病、肉芽肿病、囊性纤维化或胶稠性黏液病、α-1-抗胰蛋白酶缺乏引起之间质性肺炎)、由新冠病毒/SARS-Cov-2感染导致的急性肺损伤或继发于新冠病毒/SARS-Cov-2感染的肺纤维化。
(3)其他纤维变性疾病,例如肝桥接纤维化、肝硬化、非酒精性脂肪性肝炎(NASH)、心房纤维化、心肌内膜纤维化、陈旧性心肌梗塞、胶质瘢痕、动脉僵硬、关节纤维化、Dupuytren氏挛缩、瘢瘤、硬皮症/全身性硬化、纵膈纤维化、骨髓纤维化、Peyronie氏病、肾原性全身性纤维化、腹膜后纤维化、黏连性滑膜囊炎。
(4)发炎、自体免疫或过敏性疾病及病况,例如过敏性或非过敏性鼻炎或窦炎、慢性窦炎或鼻炎、鼻瘜肉、慢性鼻窦炎、急性鼻窦炎、气喘、小儿气喘、过敏性支气管炎、肺泡炎、气道高反应性、过敏性结膜炎、支气管扩张症、成人呼吸窘迫综合征、支气管及肺水肿、支气管炎或肺炎、嗜酸性球性蜂窝组织炎(例如Well氏综合征)、嗜酸性球性肺炎(例如吕佛勒氏综合征(Loeffler's syndrome)、慢性嗜酸性球性肺炎)、嗜酸性球性筋膜炎(例如,Shulman氏综合征)、迟发型过敏、非过敏性气喘;运动诱发的支气管收缩;慢性阻塞性肺病(COPD)、急性支气管炎、慢性支气管炎、咳嗽、肺气肿;全身性过敏反应或过敏性反应、药物过敏(例如对青霉素、头孢菌素)、由于摄入受污染色氨酸所致的嗜酸性球增多-肌痛综合征、昆虫刺伤过敏;自体免疫疾病,例如类风湿性关节炎、格雷氏病(Graves'disease)、薛格连氏综合征(Sjogren's syndrome)、牛皮癣关节炎、多发性硬化、全身性红斑狼疮、重症肌无力、免疫性血小板减少症(成人ITP、新生儿血小板减少症、儿童ITP)、免疫学溶血性贫血(自体免疫及药物诱发)、Evans氏综合征(血小板及红血球免疫性血球减少症)、新生儿Rh病、古巴士德氏综合征(Goodpasture's syndrome)(抗GBM病)、乳糜泻、自体免疫性心肌病、幼发型糖尿病;肾小球性肾炎、自体免疫性甲状腺炎、贝赛特氏病(Behcet's disease);移植物排斥(例如在移植中),包括同种异体移植物排斥或移植物抗宿主疾病;炎性肠病,例如克隆氏病(Crohn's disease)及溃疡性结肠炎;脊椎关节疾病;硬皮症;牛皮癣(包括T细胞介导的牛皮癣)及炎性皮肤病,例如皮肤炎、湿疹、异位性皮肤炎、过敏性接触性皮肤炎、荨麻疹;血管炎(例如,坏死性、皮肤及过敏性血管炎);结节性红斑;嗜酸性球性肌炎、嗜酸性球性筋膜炎、癌症伴皮肤或器官的白血球浸润;眼科疾病,例如年龄相关性黄斑退化、糖尿病视网膜病变及糖尿病黄斑水肿、角膜炎、嗜酸性球性角膜炎、角膜结膜炎、春季角膜结膜炎、结瘢、眼前段结瘢、眼睑炎、睑结膜炎、大疱性病症、疤痕性类天疱疮、结膜黑色素瘤、乳头状结膜炎、干眼症、上巩膜炎、青光眼、神经胶瘤病、环状肉芽肿、格雷氏眼病(Graves'ophthalmopathy)、眼内黑色素瘤、睑裂斑、增殖性玻璃体视网膜病变、翼状胬肉、巩膜炎、眼色素层炎、急性痛风发作、痛风或骨关节炎。
(5)疼痛,例如慢性特发性疼痛综合征、神经病性疼痛、感觉迟钝、触摸痛、偏头痛、牙齿痛及术后疼痛。
(6)抑郁症、焦虑、糖尿病性神经病变及膀胱病症,例如膀胱出口阻塞、膀胱过度活动症、膀胱炎;心肌再灌注损伤或脑缺血损伤。
因此,本发明涉及作为药剂的通式1化合物。
此外,本发明涉及通式1的化合物用于治疗和/或预防与TRPA1活性相关或由TRPA1活性调节的疾病和/或病况的用途。
此外,本发明涉及通式1的化合物用于治疗和/或预防纤维变性疾病、发炎及免疫调节病症、呼吸道或胃肠疾病或不适、眼科疾病、关节的炎性疾病及鼻咽、眼睛及皮肤的炎性疾病、疼痛及神经病症的用途。所述病症、疾病及病苦包括咳嗽、特发性肺纤维化、其他肺间质性疾病及其他纤维变性、气喘或过敏性疾病、嗜酸性球疾病、慢性阻塞性肺病、以及发炎及免疫调节病症(例如类风湿性关节炎及动脉粥样硬化)、以及疼痛及神经病症(例如急性疼痛、手术疼痛、慢性疼痛及抑郁症)及膀胱病症。
此外,本发明涉及通式1的化合物用于治疗和/或预防以下各项的用途:
(1)咳嗽,例如慢性特发性咳嗽或慢性难治性咳嗽、与气喘、COPD、肺癌、病毒后感染及特发性肺纤维化及其他肺间质性疾病相关的咳嗽。
(2)肺纤维变性疾病,例如肺炎或与胶原变性相关之间质性肺炎,例如红斑狼疮、全身性硬皮症、类风湿性关节炎、多发性肌炎及皮肌炎、特发性间质性肺炎,例如特发性肺纤维化(IPF)、非特异性间质性肺炎、呼吸性细支气管炎伴间质性肺病、脱屑性间质性肺炎、隐源性机化性肺炎、急性间质性肺炎及淋巴球性间质性肺炎、淋巴管平滑肌瘤病、肺泡蛋白质沉着症、兰格罕细胞组织球增生症、胸膜实质弹性纤维增生、已知病因之间质性肺病,例如由于职业暴露导致之间质性肺炎,例如石棉肺、硅肺病、矿工肺(煤尘)、农夫肺(干草及霉菌)、鸽友肺(鸟类)或其他职业性空中浮游触发因素(例如金属粉尘或分枝杆菌),或由治疗(例如辐射、甲胺喋呤、胺碘酮、呋喃妥因或化学治疗剂)导致之间质性肺炎,或肉芽肿疾病,例如肉芽肿性多发性血管炎、查-施二氏综合征、类肉瘤病、过敏性肺炎或由不同病因造成之间质性肺炎(例如误吸、吸入有毒气体、蒸气,支气管炎或肺炎或由心脏衰竭、X-射线、辐射、化学疗法、M.boeck症或类肉瘤病、肉芽肿病、囊性纤维化或胶稠性黏液病、α-1-抗胰蛋白酶缺乏引起之间质性肺炎)、由新冠病毒/SARS-Cov-2感染导致的急性肺损伤或继发于新冠病毒/SARS-Cov-2感染的肺纤维化。
(3)其他纤维变性疾病,例如肝桥接纤维化、肝硬化、非酒精性脂肪性肝炎(NASH)、心房纤维化、心肌内膜纤维化、陈旧性心肌梗塞、胶质瘢痕、动脉僵硬、关节纤维化、Dupuytren氏挛缩、瘢瘤、硬皮症/全身性硬化、纵膈纤维化、骨髓纤维化、Peyronie氏病、肾原性全身性纤维化、腹膜后纤维化、黏连性滑膜囊炎。
(4)发炎、自体免疫或过敏性疾病及病况,例如过敏性或非过敏性鼻炎或窦炎、慢性窦炎或鼻炎、鼻瘜肉、慢性鼻窦炎、急性鼻窦炎、气喘、小儿气喘、过敏性支气管炎、肺泡炎、气道高反应性、过敏性结膜炎、支气管扩张症、成人呼吸窘迫综合征、支气管及肺水肿、支气管炎或肺炎、嗜酸性球性蜂窝组织炎(例如Well氏综合征)、嗜酸性球性肺炎(例如吕佛勒氏综合征、慢性嗜酸性球性肺炎)、嗜酸性球性筋膜炎(例如,Shulman氏综合征)、迟发型过敏、非过敏性气喘;运动诱发的支气管收缩;慢性阻塞性肺病(COPD)、急性支气管炎、慢性支气管炎、咳嗽、肺气肿;全身性过敏反应或过敏性反应、药物过敏(例如对青霉素、头孢菌素)、由于摄入受污染色氨酸所致的嗜酸性球增多-肌痛综合征、昆虫刺伤过敏;自体免疫疾病,例如类风湿性关节炎、格雷氏病、薛格连氏综合征、牛皮癣关节炎、多发性硬化、全身性红斑狼疮、重症肌无力、免疫性血小板减少症(成人ITP、新生儿血小板减少症、儿童ITP)、免疫学溶血性贫血(自体免疫及药物诱发)、Evans氏综合征(血小板及红血球免疫性血球减少症)、新生儿Rh病、古巴士德氏综合征(抗GBM病)、乳糜泻、自体免疫性心肌病、幼发型糖尿病;肾小球性肾炎、自体免疫性甲状腺炎、贝赛特氏病;移植物排斥(例如在移植中),包括同种异体移植物排斥或移植物抗宿主疾病;炎性肠病,例如克隆氏病及溃疡性结肠炎;脊椎关节疾病;硬皮症;牛皮癣(包括T细胞介导的牛皮癣)及炎性皮肤病,例如皮肤炎、湿疹、异位性皮肤炎、过敏性接触性皮肤炎、荨麻疹;血管炎(例如,坏死性、皮肤及过敏性血管炎);结节性红斑;嗜酸性球性肌炎、嗜酸性球性筋膜炎、癌症伴皮肤或器官的白血球浸润;眼科疾病,例如年龄相关性黄斑退化、糖尿病视网膜病变及糖尿病黄斑水肿、角膜炎、嗜酸性球性角膜炎、角膜结膜炎、春季角膜结膜炎、结瘢、眼前段结瘢、眼睑炎、睑结膜炎、大疱性病症、疤痕性类天疱疮、结膜黑色素瘤、乳头状结膜炎、干眼症、上巩膜炎、青光眼、神经胶瘤病、环状肉芽肿、格雷氏眼病、眼内黑色素瘤、睑裂斑、增殖性玻璃体视网膜病变、翼状胬肉、巩膜炎、眼色素层炎、急性痛风发作、痛风或骨关节炎。
(5)疼痛,例如慢性特发性疼痛综合征、神经病性疼痛、感觉迟钝、触摸痛、偏头痛、牙齿痛及术后疼痛。
(6)抑郁症、焦虑、糖尿病性神经病变及膀胱病症,例如膀胱出口阻塞、膀胱过度活动症、膀胱炎;心肌再灌注损伤或脑缺血损伤。
在其他方面中,本发明涉及通式1的化合物,其用于治疗和/或预防以上提及的疾病及病况。
在其他方面中,本发明涉及通式1的化合物用于制备药剂的用途,该药剂用于治疗和/或预防以上提及的疾病及病况。
在本发明的其他方面中,本发明涉及用于治疗或预防以上提及的疾病及病况的方法,该方法包含将有效量的通式1化合物施用给人类。
组合疗法
本发明化合物可进一步与一种或多种、优选一种其他治疗剂组合。根据一个实施方案,额外治疗剂选自以下的群:可用于治疗上文所述疾病或病况、特定地与纤维变性疾病、发炎及免疫调节病症、呼吸道或胃肠疾病或不适、关节的炎性疾病或鼻咽、眼睛及皮肤的炎性疾病或病况(例如咳嗽、特发性肺纤维化、其他肺间质性疾病、气喘或过敏性疾病、嗜酸性球疾病、慢性阻塞性肺病、异位性皮肤炎)以及自体免疫性病变(例如类风湿性关节炎及动脉粥样硬化)相关的疾病或病况的治疗剂或可用于治疗眼科疾病、疼痛及抑郁症的治疗剂。
适于所述组合的其他治疗剂特定包括那些(例如)加强一种或多种活性物质关于所提及适应症中之一者的治疗效应者和/或允许减少一种或多种活性物质的剂量者。
因此,本发明化合物可与一种或多种选自由以下组成的组的其他治疗剂组合:抗纤维化剂、止咳剂、消炎剂、抗异位性皮肤炎药剂、止痛药、抗发厥剂、抗焦虑剂、镇静剂、骨骼肌松弛剂或抗抑郁剂。
抗纤维化剂例如为尼达尼布(nintedanib)、吡非尼酮(pirfenidone)、磷酸二酯酶-IV(PDE4)抑制剂(例如罗氟司特(roflumilast))、自分泌运动因子抑制剂(autotaxininhibitor)(例如GLPG-1690或BBT-877);结缔组织生长因子(CTGF)阻断抗体,例如潘瑞鲁单抗(Pamrevlumab);B细胞活化因子受体(BAFF-R)阻断抗体,例如拉那鲁单抗(Lanalumab);α-V/β-6阻断抑制剂,例如BG-00011/STX-100、重组正五聚蛋白-2(recombinant pentraxin-2,PTX-2),例如PRM-151;c-Jun N-末端激酶(JNK)抑制剂,例如CC-90001;半乳糖凝集素-3抑制剂,例如TD-139;G蛋白偶联受体84(GPR84)抑制剂,例如GLPG-1205;G蛋白偶联受体84/G蛋白偶联受体40双重抑制剂,例如PBI-4050;含Rho相关卷曲螺旋蛋白激酶2(ROCK2)抑制剂,例如KD-025;热休克蛋白47(HSP47)小干扰RNA,例如BMS-986263/ND-L02-s0201;Wnt路径抑制剂,例如SM-04646;LD4/PDE3/4抑制剂,例如Tipelukast;组氨酰基tRNA合成酶(HARS)的重组免疫调节结构域,例如ATYR-1923;前列腺素合酶抑制剂,例如ZL-2102/SAR-191801;15-羟基-二十碳五烯酸(15-HEPE,例如DS-102);赖氨酰氧化酶,如2(LOXL2)抑制剂,例如PAT-1251、PXS-5382/PXS-5338;磷酸肌醇3-激酶(PI3K)/哺乳动物雷帕霉素靶蛋白(mTOR)双重抑制剂,例如HEC-68498;钙蛋白酶抑制剂,例如BLD-2660;促分裂原活化蛋白激酶激酶激酶(MAP3K19)抑制剂,例如MG-S-2525;壳质酶抑制剂,例如OATD-01;促分裂原活化蛋白激酶活化蛋白激酶2(MAPKAPK2)抑制剂,例如MMI-0100;转变生长因子β1(TGF-beta1)小干扰RNA,例如TRK250/BNC-1021;或溶血磷脂酸受体拮抗剂,例如BMS-986278。
止咳剂例如为嘌呤受体3(P2X3)受体拮抗剂,例如吉法匹生(gefapixant)、S-600918、BAY-1817080或BLU-5937;神经激肽1(NK-1)受体拮抗剂,例如奥维匹坦、阿瑞匹坦;烟碱型乙酰胆碱受体α7亚单位刺激物,例如ATA-101/布拉他尼林(bradanicline);可待因(codeine)、加巴喷丁(gabapentin)、普瑞巴林(pregablin)或阿奇霉素(azithromycin)。
消炎剂例如为皮质类固醇,例如普赖苏浓(prednisolone)或地塞米松(dexamethasone);环氧化酶-2(COX2)抑制剂,例如塞来昔布(celecoxib)、罗非昔布(rofecoxib)、帕瑞昔布(parecoxib)、伐地昔布(valdecoxib)、德拉昔布(deracoxib)、依托昔布(etoricoxib)或罗美昔布(lumiracoxib);前列腺素E2拮抗剂;白三烯B4拮抗剂;白三烯D4拮抗剂,例如孟鲁司特(montelukast);5-脂肪加氧酶抑制剂;或其他非类固醇消炎剂(NSAID),例如阿斯匹林(aspirin)、双氯芬酸(diclofenac)、二氟尼柳(diflunisal)、依托度酸(etodolac)、布洛芬(ibuprofen)或吲哚美辛(indomethacin)。
抗异位性皮肤炎剂例如为环孢素(cyclosporin)、甲胺喋呤(methotrexate)、吗替麦考酚酯(mycophenolate mofetil)、硫唑嘌呤(azathioprine)、磷酸二酯酶抑制剂(例如阿普斯特(apremilast)、克立硼罗(crisaborole))、Janus相关激酶(JAK)抑制剂(例如托法替尼(tofacitinib))、针对IL-4/IL-13的中和抗体(例如度普利尤单抗(dupilumab))、IL-13(例如来瑞珠单抗(lebrikizumab)、曲罗芦单抗(tralokinumab))及IL-31(奈莫利珠单抗(nemolizumab))。
止痛药例如为类鸦片型,例如吗啡(morphine)、氧化吗啡(oxymorphine)、左啡诺(levorphanol)、羟考酮(oxycodone)、丙氧芬(propoxyphene)、纳美芬(nalmefene)、芬太尼(fentanyl)、氢可酮(hydrocodone)、氢吗啡酮(hydromorphone)、美利皮定(meripidine)、美沙酮(methadone)、纳洛芬(nalorphine)、那若松(naloxone)、那曲酮(naltrexone)、丁基原啡因(buprenorphine)、布托啡诺(butorphanol)、纳布啡(nalbuphine)、戊唑辛(pentazocine);或非类鸦片型,例如乙酰胺酚(acetaminophen)。
抗抑郁剂例如为三环抗抑郁剂,例如阿米替林(amitriptyline)、氯米帕明(clomipramine)、地昔帕明(desipramine)、多虑平(doxepin)、地昔帕明、伊米帕明(imipramine)、去甲替林(nortriptyline);选择性血清素再摄取抑制剂抗抑郁剂(SSRI),例如氟西汀(fluoxetine)、帕罗西汀(paroxetine)、舍曲林(sertraline)、西酞普兰(citalopram)、依地普仑(escitalopram);去甲肾上腺素再摄取抑制剂抗抑郁剂(SNRI),例如麦普替林(maprotiline)、洛非帕明(lofepramine)、米氮平(mirtazapine)、羟丙替林(oxaprotiline)、非唑拉明(fezolamine)、托莫西汀(tomoxetine)、米安舍林(mianserin)、安非他酮(buproprion)、羟基安非他酮(hydroxybuproprion)、诺米芬辛(nomifensine)、维洛沙嗪(viloxazine);双重血清素-去甲肾上腺素再摄取抑制剂抗抑郁剂(SNRI),例如度洛西汀(duloxetine)、万拉法辛(venlafaxine)、地万拉法辛(desvenlafaxine)、左米那普仑(levomilnacipran);非典型抗抑郁药,例如曲唑酮(trazodone)、米氮平、沃替西汀(vortioxetine)、维拉佐酮(vilazodone)、安非他酮;或单胺氧化酶抑制剂抗抑郁剂(MAOI),例如强内心百乐明(tranylcypromine)、苯乙肼(phenelzine)或异唑肼(isocarboxazid)。
抗焦虑剂例如为苯并二氮杂卓,例如阿普唑仑(alprazolam)、溴西泮(bromazepam)、氯二氮平(chlordiazepoxide)、可那氮平(clonazepam)、氯拉卓酸(clorazepate)、二氮平(diazepam)、氟西泮(flurazepam)、氯羟去甲安定(lorazepam)、去甲羟基安定(oxazepam)、替马西泮(temazepam)、三唑仑(triazolam)或托非索泮(tofisopam);或其为非苯并二氮杂卓类安眠药,例如右旋佐匹克隆(eszopiclone)、扎来普隆(zaleplon)、唑吡坦(zolpidem)或佐匹克隆(zopiclone);或其为氨基甲酸酯,例如甲丙胺酯(meprobamate)、肌安宁(carisoprodol)、泰巴氨酯(tybamate)或劳氨酯(lorbamate);或其为抗组织胺,例如羟嗪(hydroxyzine)、氯苯那敏(chlorpheniramine)或苯海拉明(diphenhydramine)。
镇静剂例如为巴比妥酸盐镇静剂,例如异戊巴比妥(amobarbital)、阿普比妥(aprobarbital)、仲丁巴比妥(butabarbital)、布他比妥(butabital)、甲苯巴比妥(mephobarbital)、美沙比妥(metharbital)、美索比妥(methohexital)、戊巴比妥(pentobarbital)、司可巴比妥(secobarbital)、他布比妥(talbutal)、硫阿米妥(thiamylal)或硫喷妥(thiopental);或其为非巴比妥酸盐类镇静剂,例如格鲁米特(glutethimide)、甲丙胺酯(meprobamate)、甲喹酮(methaqualone)或氯醛比林(dichloralphenazone)。
骨骼肌松弛剂例如为巴氯芬(baclofen)、甲丙胺酯、肌安宁、环苯扎林(cyclobenzaprine)、美他沙酮(metaxalone)、美索巴莫(methocarbamol)、替扎尼定(tizanidine)、氯唑沙宗(chlorzoxazone)或邻甲苯海拉明(orphenadrine)。
其他适宜组合配对物为乙酰胆碱酯酶抑制剂,例如多奈派齐(donepezil);5-HT-3拮抗剂,例如昂丹司琼(ondansetron);代谢型谷氨酸受体拮抗剂;抗心律不整剂,例如墨西律定(mexiletine)或苯妥英(phenytoin);或NMDA受体拮抗剂。
进一步适宜组合配对物为失禁药物,例如抗胆碱剂,例如羟布托尼(oxybutynin)、托特罗定(tolterodine)、达非那新(darifenacin)、非索罗定(fesoterodine)、索利那新(solifenacin)或曲司铵(trospium);或其为膀胱肌肉松弛剂,例如米拉贝隆(mirabegron);或其为α阻断剂,例如坦洛新(tamsulosin)、阿夫唑嗪(alfuzosin)、西洛多辛(silodosin)、多沙唑嗪(doxazosin)或特拉唑嗪(terazosin)。
上文所提及组合配对物的剂量通常为正常推荐最低剂量的1/5至最高正常推荐剂量的1/1。
因此,在另一方面中,本发明涉及本发明化合物与上文及下文所述一种或多种其他治疗剂组合的用途,其用于治疗可受TRPA1影响或由TRPA1介导的疾病或病况,特别地如上文及下文所述的疾病或病况。
在其他方面中,本发明涉及用于治疗患者的可受TRPA1抑制影响的疾病或病况的方法,其包括向需要该治疗的患者施用治疗有效量的式(I)化合物或其药学上可接受的盐与治疗有效量的一种或多种其他治疗剂的组合的步骤。
在其他方面中,本发明涉及式(I)化合物或其药学上可接受的盐与一种或多种其他治疗剂的组合的用途,其用于治疗有需要的患者的可受TRPA1抑制影响的疾病或病况。
在另一方面中,本发明涉及用于治疗患者中由TRPA1活性介导的疾病或病况的方法,其包括向需要该治疗的患者、优选人类施用治疗有效量的本发明化合物与治疗有效量的上文及下文中所述一种或多种其他治疗剂的步骤。
本发明化合物与其他治疗剂组合的使用可同时或在交错时间进行。
本发明化合物及一种或多种其他治疗剂二者可一起存在于一种调配物(例如片剂或胶囊)中或分开存在于两种相同或不同调配物(例如所谓的部分试剂盒(kit-of-parts)形式)中。
因此,在另一方面中,本发明涉及药物组合物,其包含本发明化合物及上文及下文所述的一种或多种其他治疗剂以及任选一种或多种惰性载剂和/或稀释剂。
在再另一方面中,本发明涉及本发明化合物在咳嗽测量装置中的用途。
根据以下更详细的例子可了解本发明的其他特征及优点,其以示例方式说明本发明的原理。
制备
本发明化合物及其中间体可使用本领域技术人员已知且阐述于有机合成文献中的合成方法来获得。优选地,化合物以类似于下文更全面解释、特定地如实验部分中所述的制备方法来获得。在一些情形中,可改变实施反应步骤的顺序。亦可使用本领域技术人员已知但本文未详细阐述的反应方法的变化形式。
本领域技术人员在研究下文方案后将了解制备本发明化合物的一般方法。起始材料或中间体中的任何官能基可使用常规保护基团进行保护。所述保护基团可在反应顺序内的适宜阶段使用本领域技术人员熟知的方法再次裂解。
本发明化合物通过下文所述合成方法来制备,其中通式的取代基具有上文所给含义。所述方法意欲作为本发明的说明,而非限制其目标物及所述实施例所主张化合物的范围。在未阐述起始化合物的制备的情形中,其为市面可获得或可以与本文中所述已知化合物或方法类似的方式制备。文献中所阐述的物质为根据公开的合成方法制备。缩写定义于实施例部分中。
方案1:
在方案1中,式I及II的化合物可经由在碱(例如碳酸钾)的存在下利用氯亚甲基-噁二唑(D)使适当杂芳香族中间体(A)或(B)进行N-烷基化来合成。或者,羧酸(C)可利用例如CDI活化并与二羟基丙脒(E)缩合,以获得类型II的化合物。
方案2:
在方案2中,将子结构(F)的α-氰基酮以对映选择性方式通过使用适当催化系统还原,该催化系统使用过渡金属络合物(例如Ru或Ir)与手性配体(例如[(1S,2S)-(-)-2-氨基-1,2-二苯基乙基](4-甲苯磺酰基)酰胺基)的组合及氢源(例如甲酸三乙胺络合物)。将羟基胺添加至相应氰基-醇(G)以提供二羟基丙脒(E)。氯亚甲基-噁二唑(D)的死循环可通过将反应混合物与氯乙酰氯一起在碱(例如DIPEA)的存在下搅拌来达成。
方案3:
在方案3中,4,5-二氯-2H-哒嗪-3-酮可利用适当保护基团(例如,苄基氧基甲基氯(Bom-Cl))在碱(例如,DBU)的存在下N-烷基化。随后,用亚硝酸盐取代4-Cl且用氢氧化物取代(H)的5-Cl位置以提供中间体(J),其可以进一步与氨反应以得到(K)。硝基使用适当触媒(例如PtO2)在氢气氛下还原,获得二-胺(L),其可进一步与羰基二咪唑(CDI)反应以获得(M)。最后,利用甲基化试剂(例如碘甲烷)在碱(例如碳酸钾)的存在下进行二-烷基化并使保护基团裂解获得中间体(A)。
方案4:
在方案4中,咪唑(O)可利用适当甲基化试剂(例如碘甲烷(MeI))在碱(例如碳酸钾)的存在下进行烷基化。中间体(P)可经由利用例如二-异丁基氢化铝(DIBAL-H)还原及随后利用例如氧化锰(IV)氧化反应为醛(R)。(R)与肼在酸性条件下缩合获得(S),其可进一步还原为中间体(B)。最后,(B)利用溴乙酸叔丁基酯在碱(例如碳酸钾)的存在下烷基化以提供酯(T),该酯(T)可在酸性条件下水解以获得(C)。
实施例
制备
本发明化合物及其中间体可使用本领域技术人员已知且有机合成文献中阐述的合成方法(例如使用“Comprehensive Organic Transformations”,第2版,RichardC.Larock,John Wiley&Sons,2010及“March’s Advanced Organic Chemistry”,第7版,Michael B.Smith,John Wiley&Sons,2013中所述的方法)获得。优选地,化合物为类似于下文更全面地解释、特别地如实验部分中所述的制备方法获得。在一些情形中,可改变实施反应方案所采用的顺序。亦可使用本领域技术人员已知但本文未详细阐述的所述反应的变化形式。本领域技术人员在研究下文方案后将了解用于制备本发明化合物的一般方法。起始化合物可自市场购得或可通过文献或本文中阐述的方法来制备,或可以类似或相似的方式来制备。在实施反应之前,可使用常规保护基团来保护起始化合物中的任何相应官能基。所述保护基团可在反应序列内的适宜阶段使用本领域技术人员熟知和文献(例如“Protecting Groups”,第3版,Philip J.Kocienski,Thieme,2005及“Protective Groupsin Organic Synthesis”,第4版,Peter G.M.Wuts,Theodora W.Greene,John Wiley&Sons,2006)中所阐述的方法再次裂解。术语“环境温度”及“室温”可互换使用且指定约20℃的温度,例如介于19℃与24℃之间。
缩写:
/>
中间体的制备
中间体I
中间体I.1(一般途径)
(3S)-3-(4-氯苯基)-3-羟基丙腈
在惰性气氛下将10.0g(55.7mmol)4-氯苯甲酰基乙腈添加至100mL ACN。添加142mg(0.23mmol)氯([(1S,2S)-2-氨基-1,2-二苯基乙基](4-甲苯磺酰基)酰胺基)(均三甲苯基)钌(II)(CAS174813-81-1),随后逐滴添加8.30mL(19.8mmol)甲酸三乙胺络合物(5:2)。在RT下搅拌3h后,在真空中去除溶剂。向剩余粗制混合物中添加水且此混合物利用EtOAc萃取两次。将有机层合并,经MgSO4干燥,过滤,并在真空中去除溶剂,以提供中间体I.1。
C9H8ClNO (M=181.6g/mol)
ESI-MS: 226[M+HCOO]-
Rt(HPLC): 0.81min(方法B)
以下化合物为使用类似于针对中间体I.1所述那些的程序使用适当起始材料制备。如本领域技术人员所了解,所述类似实施例可涉及一般反应条件中的变化。
/>
中间体II
中间体II.1(一般途径)
(3S)-3-(4-氯苯基)-N,3-二羟基丙脒
向于100mL MeOH中的9.82g(54.1mmol)(3S)-3-(4-氯苯基)-3-羟基丙腈(中间体I.1)添加8.00mL(136mmol)羟基胺(50%于水中)并将混合物在75℃下搅拌1.5h。冷却至RT后,在真空中去除所有挥发物以获得粗制产物,其不经进一步纯化即使用。
C9H11ClN2O2 (M=214.6g/mol)
ESI-MS: 215[M+H]+
Rt(HPLC): 0.60min(方法B)
以下化合物为使用类似于针对中间体II.1所述那些的程序使用适当起始材料制备。如本领域技术人员所了解,所述类似实施例可涉及一般反应条件中的变化。
/>
中间体III
中间体III.1(一般途径)
(1S)-2-[5-(氯甲基)-1,2,4-噁二唑-3-基]-1-(4-氯苯基)乙-1-醇
向于55mL NMP中的11.2g(52.4mmol)中间体II.1中添加10.0mL(57.8mmol)DIPEA。将混合物冷却至0℃,然后缓慢添加溶于5mL NMP中的4.60mL(57.7mmol)氯乙酰氯并将混合物于0℃下搅拌45min.。然后将混合物加热至高达95℃并继续搅拌4h。冷却至RT后,添加200mL水并将所得混合物利用EtOAc萃取三次。将有机层合并,经MgSO4干燥,过滤并在真空中去除溶剂。残余物通过柱色谱(硅胶;PE/EtOAc,7/3)纯化。
C11H10Cl2N2O2 (M=273.1g/mol)
ESI-MS: 271[M-H]-
Rt(HPLC): 0.93min(方法B)
以下化合物为使用类似于针对中间体III.1所述那些的程序使用适当起始材料制备。如本领域技术人员所了解,所述类似实施例可涉及一般反应条件中的变化。
/>
中间体IV
中间体IV.1(一般途径)
3-(6-氟-1-苯并噻吩-2-基)-3-氧代丙腈
/>
在惰性气氛下在RT下向于9.0mL无水甲苯及0.78mL无水ACN中的0.63g(3.00mmol)6-氟-1-苯并噻吩-2-甲酸甲酯中添加0.36g(9.00mmol)的NaH(60%于油中)。将混合物加热至回流并搅拌16h,冷却至室温,倾倒于冰/水(30mL)上,用2M HCl处理以达到pH=1。添加EtOAc(20mL)且相分离。将水相再次用EtOAc(20mL)萃取,合并的有机相用盐水(20mL)洗涤,且在减压下去除溶剂。通过硅胶柱色谱使用EtOAc/己烷的梯度(30%至40%)纯化粗产物。
C11H6FNOS (M=219.23g/mol)
ESI-MS: 218[M-H]-
Rt(HPLC): 3.31min(L)
以下化合物为使用类似于针对中间体IV.1所述那些的程序使用适当起始材料制备。如本领域技术人员所了解,所述类似实施例可涉及一般反应条件中的变化。
中间体V
中间体V.1
2-[(苄基氧基)甲基]-4,5-二氯-2,3-二氢哒嗪-3-酮
在0℃下向300g(1.82mol)4,5-二氯-2H-哒嗪-3-酮于2L DMF中的搅拌混合物中添加262g(1.72mol)1,8-二氮杂二环十一-7-烯,随后添加370g(2.37mol)氯甲氧基甲基-苯。将反应混合物加热至环境温度并搅拌总共16h。将混合物用水稀释并用乙酸乙酯(3x)萃取。合并的有机萃取物经Na2SO4干燥并浓缩。通过柱色谱(SiO2,EtOAc/PE)纯化残余物,以获得期望产物。
C12H11N3O5 (M=285.1g/mol)
ESI-MS: 285/287[M+H]+
Rt(HPLC): 2.2min(K)
中间体V.2
2-[(苄基氧基)甲基]-4-羟基-5-硝基-2,3-二氢哒嗪-3-酮
向于700mL DMF及300mL水中的85.0g(298mmol)中间体V.1添加82.3g(1.19mol)亚硝酸钠。将反应混合物在85℃下搅拌24h,然后冷却至环境温度,用盐酸水溶液(5N)酸化并调整至pH4。将混合物过滤并将所收集固体在真空下干燥以获得期望产物。
C12H11N3O5 (M=277.2g/mol)
ESI-MS: 278[M+H]+
Rt(HPLC): 1.71min(方法K)
中间体V.3
4-氨基-2-[(苄基氧基)甲基]-5-硝基-2,3-二氢哒嗪-3-酮
向50.0g(180mmol)的中间体V.2中添加3.75L氨的MeOH饱和溶液。将反应混合物在高压釜反应器中加热至130℃过夜。冷却至环境温度后,混合物进一步冷却至0℃。沉淀的固体通过过滤收集并通过柱色谱(SiO2,DCM/MeOH梯度)纯化,以获得期望产物。
C12H12N4O4 (M=276.2g/mol)
ESI-MS: 275[M-H]-
Rt(HPLC): 1.76min(方法J)
中间体V.4
4,5-二氨基-2-[(苄基氧基)甲基]-2,3-二氢哒嗪-3-酮
向30.0g(109mmol)中间体V.3于3650mL EtOH/EtOAc(4:1)中的搅拌混合物中添加2.47g(10.9mmol)氧化铂(IV)。通过使Ar穿过溶剂达15min使混合物脱气。施加氢气氛(1atm)并将反应混合物搅拌16h。在去除氢气氛后,混合物借助硅藻土垫过滤且使滤液浓缩,以获得期望化合物。
C12H14N4O2 (M=246.3g/mol)
ESI-MS: 247[M+H]+
Rt(HPLC): 1.62min(方法K)
中间体V.5
5-[(苄基氧基)甲基]-1H,2H,3H,4H,5H-咪唑并[4,5-d]哒嗪-2,4-二酮
向29.0g(118mmol)中间体V.4于500mL THF中的搅拌混合物中添加38.2g(236mmol)1,1’-羰基二咪唑并将混合物在回流下搅拌16h。冷却至环境温度后,借助烧结漏斗过滤来收集沉淀物。所收集固体进一步利用THF洗涤并在真空下干燥,以获得期望产物。
C13H12N4O3 (M=272.3g/mol)
ESI-MS: 273[M+H]+
Rt(HPLC): 1.31min(方法J)
中间体V.6
5-[(苄基氧基)甲基]-1,3-二甲基-1H,2H,3H,4H,5H-咪唑并[4,5-d]哒嗪-2,4-二酮
在室温下向28.0g(103mmol)中间体V.5于250mL DMF中的搅拌溶液中添加42.6g(309mmol)碳酸钾并将混合物搅拌30min。然后将其冷却至0℃并添加58.4g(411mmol)碘甲烷。加热至环境温度后,将反应混合物搅拌16h。通过添加水使其骤冷并利用乙酸乙酯(3x)萃取。合并的有机萃取物用冷水洗涤以去除DMF,经Na2SO4干燥并浓缩。残余物用EtOAc/石油醚(1:1)洗涤,以获得期望化合物。
C15H16N4O3 (M=300.3g/mol)
ESI-MS: 301[M+H]+
Rt(HPLC): 1.78min(方法K)
1H NMR(400MHz,DMSO-d6)δppm 3.37(s,3H),3.55(s,3H),4.63(s,2H),5.52(s,2H),7.25-7.34(m,5H),8.35(s,1H)。
中间体V.7
1,3-二甲基-1H,2H,3H,4H,5H-咪唑并[4,5-d]哒嗪-2,4-二酮
制备20.0g(66.6mmol)中间体V.6于500mL DCM的混合物并冷却至-78℃。添加58.4g(499mmol)三氯化硼于DCM中的溶液并将反应混合物在相同温度下搅拌2h。然后添加500mL甲醇/DCM的等摩尔混合物并将反应混合物在-78℃下再搅拌2h。加热至环境温度后,将混合物再搅拌30min。将混合物浓缩并与MeOH一起共蒸发(5次)以去除痕量硼酸甲酯。将残余物与MTBE一起研磨并将所收集固体在真空下干燥,以获得期望化合物。
C7H8N4O2 (M=180.2g/mol)
ESI-MS: 181[M+H]+
Rt(HPLC): 0.75min(方法K)
1H NMR(500MHz,DMSO-d6)δppm 3.36(s,3H),3.52(s,3H),8.25(s,1H),12.94(s,1H)。
中间体VI
中间体VI.1
2-溴-1-甲基咪唑-4,5-二甲酸4,5-二甲酯
在环境温度下向于300mL DMF中的30.0g(114mmol)2-溴-1H-咪唑-4,5-二甲酸4,5-二甲酯(CAS:705280-65-5)添加32.4g(228mmol)碘甲烷及31.5g(228mmol)碳酸钾。将所得反应混合物在环境温度下搅拌16h。然后将混合物浓缩,用水稀释并用乙酸乙酯萃取。将有机萃取物经硫酸钠干燥并浓缩。通过柱色谱(硅胶,PE/EtOAc 30/70)纯化残余物,以获得期望产物。
C8H9BrN2O4 (M=277.1g/mol)
ESI-MS: 277/279[M+H]+
Rt(HPLC): 1.64min(方法K)
中间体VI.2
2-溴-5-甲酰基-3-甲基咪唑-4-甲酸甲酯
将20.0g(72.2mmol)2-溴-1-甲基咪唑-4,5-二甲酸4,5-二甲酯于800mL THF中的混合物冷却至-78℃并添加121mL(180.5mmol,25wt%于甲苯中)DIBAL-H溶液。将反应混合物搅拌2h并在此时期期间缓慢加热至-20℃。然后将反应混合物用冰冷的水及酒石酸钾钠骤冷。然后用乙酸乙酯萃取混合物。合并的有机萃取物用饱和盐水洗涤,经硫酸钠干燥并浓缩。残余物含有85%纯度的中间体醇且不经进一步纯化即用于下一步骤中。
于环境温度下向15.0g(85%纯度,51.2mmol)2-溴-5-(羟基甲基)-3-甲基咪唑-4-甲酸乙酯于150mL二氯甲烷中的混合物中添加178g(2.05mol)氧化锰(IV)。将所得悬浮液在环境温度下搅拌16h。然后借助硅藻土过滤反应混合物。将滤液在减压下浓缩以获得期望产物。
C7H7BrN2O3 (M=247.1g/mol)
ESI-MS: 247/249[M+H]+
Rt(HPLC): 1.51min(方法K)
中间体VI.3
2-溴-3-甲基-5H-咪唑并[4,5-d]哒嗪-4-酮
在环境温度下向8.0g(32.4mmol)2-溴-5-甲酰基-3-甲基咪唑-4-甲酸甲酯于80mL乙醇中的混合物中添加1.95mL(38.9mmol)水合肼。将反应混合物在环境温度下搅拌15min,然后添加7.4mL(130mmol)乙酸。然后将反应混合物加热至80℃并在此温度下搅拌30min。冷却至环境温度后,通过过滤收集沉淀的固体。进一步利用乙醚洗涤多次并在真空下干燥以获得期望产物。
C6H5BrN4O (M=229.0g/mol)
ESI-MS: 229/231[M+H]+
Rt(HPLC): 1.34min(方法K)
中间体VI.4
1-甲基-1H,6H,7H-咪唑并[4,5-d]哒嗪-7-酮氢溴酸盐
在高压釜反应器中向5.3g(23.1mmol)2-溴-1-甲基-1H,6H,7H-咪唑并[4,5-d]哒嗪-7-酮于75mL MeOH中的混合物中添加200mg Pd/C(10%)。将反应混合物以上的空间抽真空并填充50psi氢压力。将反应混合物在环境温度下在50psi氢压力下搅拌过夜。去除氢并用氮气回填之后,反应混合物用300mL温水稀释并过滤。将滤液浓缩至干燥以获得期望产物。
C6H6N4O*HBr (M=231.1g/mol)
ESI-MS: 151[M-HBr+H]+
Rt(HPLC): 0.12min(方法C)
中间体VI.5
2-{1-甲基-7-氧代-1H,6H,7H-咪唑并[4,5-d]哒嗪-6-基}乙酸叔丁基酯
向于25mL DMF中的2.00g(8.66mmol)中间体VI.4中添加2.99g(21.6mmol)K2CO3并将混合物在RT下搅拌10min。添加1.90mL(12.98mmol)溴乙酸叔丁基酯且在RT下的搅拌持续4h。将反应混合物倾倒于50mL水上并用EtOAc萃取。有机层用MgSO4及木炭处理,过滤并在减压下浓缩。将粗制材料与异丙醇一起搅拌,过滤,并在50℃下干燥收集的沉淀物,以获得期望产物。
C12H16N4O3 (M=264.28g/mol)
ESI-MS: 265[M+H]+
Rt(HPLC): 0.82min(方法B)
中间体VI.6
2-{1-甲基-7-氧代-1H,6H,7H-咪唑并[4,5-d]哒嗪-6-基}乙酸盐酸盐
向于10mL二噁烷中的1.0g(3.78mmol)中间体VI.5中添加20mL于二噁烷中的HCl(4mol/L)并将反应混合物在RT下搅拌3天。将沉淀物滤出,用异丙醇洗涤,并在50℃下干燥以获得期望产物。
C8H8N4O3*HCl (M=244.6g/mol)
ESI-MS: 209[M-HCl+H]+
Rt(HPLC): 0.42min(方法B)
最终化合物的制备
实施例1(一般程序)
5-({3-[(2S)-2-(4-氯苯基)-2-羟基乙基]-1,2,4-噁二唑-5-基}甲基)-1,3-二甲基-1H,2H,3H,4H,5H-咪唑并[4,5-d]哒嗪-2,4-二酮
向于5ml DMF中的200mg(1.11mmol)中间体V.7中添加380mg(2.75mmol)K2CO3并将混合物在RT下搅拌10min。随后,添加于5ml DMF中的250mg(0.92mmol)中间体III.1并继续搅拌过夜。将反应混合物过滤且滤液通过反相HPLC(ACN/H2O梯度,0.1%TFA)纯化,以获得期望产物。
C18H17ClN6O4 (M=416.8g/mol)
ESI-MS: 417[M+H]+
Rt(HPLC): 0.86min(方法B)
1H NMR(400MHz,DMSO-d6)δppm:2.92-3.05(m,2H),3.39(s,3H),3.53(s,3H),4.92-4.99(m,1H),5.63-5.64(m,2H),7.32-7.37(m,4H),8.40(s,1H)。
以下化合物使用类似于针对实施例1一般程序所述那些的程序使用适当起始材料制备。
如本领域技术人员所了解,所述类似实施例可涉及一般反应条件中的变化。
/>
以上表中所述化合物的分析数据:
/>
/>
实施例8
6-({3-[(2S)-2-(4-溴苯基)-2-羟基乙基]-1,2,4-噁二唑-5-基}甲基)-1-甲基-1H,6H,7H-咪唑并[4,5-d]哒嗪-7-酮
向于3ml DMF中的73mg(0.30mmol)中间体VI.6添加52μL(0.30mmol)DIPEA及58mg(0.36mmol)CDI并将混合物在RT下搅拌2min。随后,添加78mg(0.30mmol)中间体II.6并在100℃下继续搅拌4h。冷却至环境温度后,通过反相HPLC(ACN/H2O梯度,0.1% TFA)纯化反应混合物,以获得期望产物。
C17H1Br1N6O3 (M=431.2g/mol)
ESI-MS: 431/433[M+H]+
Rt(HPLC): 0.86min(方法B)
1H NMR(400MHz,DMSO-d6)δppm:2.90-3.05(m,2H),4.05(s,3H),4.94(dd,J=7.8,5.8Hz,1H),5.65(s,2H),7.26-7.32(m,2H),7.44-7.50(m,2H),8.40(s,1H),8.50(s,1H)
分析型HPLC方法
方法A
分析型柱:XBridge BEH C18_2.1x30mm,1.7μm;柱温度:60℃
方法B
分析型柱:Stable Bond(Agilent)1.8μm;3.0x30mm;柱温度:60℃
方法C
分析型柱:Sunfire(Waters)2.5μm;3.0x30mm;柱温度:60℃
方法D
制备型柱:XBridge(Waters)C18_3.0x30mm_2.5μm;柱温度:60℃
方法E
XBridge C18_3.0x30mm_2.5μm(Waters);柱温度:60℃
方法F
制备型柱:Sunfire(Waters)C18_3.0x30mm_2.5μm;柱温度:60℃
方法G
分析型柱:XBridge C18(Waters)2.5μm;3.0x30mm;柱温度:60℃
方法H
分析型柱:Sunfire C18(Waters)2.5μm;3.0x30mm;柱温度:60℃
方法I
分析型柱:Sunfire(Waters)C18_2.1x30mm_2.5μm;柱温度:60℃
方法J
分析型柱:AQUITY UPLC BEH C18_2.1x50mm_1.7μm;柱温度:35℃
方法K
分析型柱:AQUITY UPLC BEH C18_2.1x50mm_1.7μm;柱温度:35℃
方法L
分析型柱:AQUITY UPLC C18_2.1x50mm_1.8μm.柱温度:25℃
方法M
分析型柱:AQUITY UPLC C18_2.1x50mm_1.8μm.柱温度:25℃
方法N
分析型柱:XBridge Phenyl_2.1x30mm,1.7μm;柱温度:60℃。
Claims (12)
1.一种式(I)化合物,
其中
A选自由以下组成的组:苯基、噻吩基、苯并噻吩基及苯并呋喃基,
且其中A未经取代或经由卤素及C1-4-烷基组成的基团R1中一或两个成员取代;
或A为
E为选自由以下组成的组:
及/>
2.根据权利要求1的式(I)化合物,其中R1选自由以下组成的组:Br、Cl、F及H3C。
3.根据权利要求1或2的式(I)化合物,其A选自由以下组成的组:
及/>
且其中A未经取代或经该基团R1的一或两个成员取代,
或
A为
4.根据权利要求1的式(I)化合物,其A选自由以下组成的组:
及
5.根据权利要求1至4中任一项的式(I)化合物,其选自
6.根据权利要求1至4中任一项的式(I)化合物,其选自
7.根据权利要求1的式(I)化合物,其选自由以下组成的组:
及
8.一种根据权利要求1至7中任一项的化合物的盐,特别是药学上可接受的盐。
9.一种药物组合物,其包含至少一种根据权利要求1至7中任一项的式I化合物或其药学上可接受的盐及一种或多种药学上可接受的赋形剂。
10.根据权利要求1至7中任一项的式(I)化合物或其药学上可接受的盐,其用作药剂。
11.根据权利要求1至7中任一项的式(I)化合物或其药学上可接受的盐,其用于治疗或预防炎性气道疾病或纤维变性疾病或咳嗽。
12.根据权利要求1至7中任一项的式(I)化合物或其药学上可接受的盐,其用于治疗或预防特发性肺疾病(idiopathic lung disease;IPF)或咳嗽。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21168431.1 | 2021-04-14 | ||
EP21168431 | 2021-04-14 | ||
PCT/EP2022/059818 WO2022219015A1 (en) | 2021-04-14 | 2022-04-13 | IMIDAZO[4,5-d]PYRIDAZINONYL DERIVATIVES AS TRPA1 INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117545758A true CN117545758A (zh) | 2024-02-09 |
Family
ID=75539074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280025202.4A Pending CN117545758A (zh) | 2021-04-14 | 2022-04-13 | 作为TRPA1抑制剂的咪唑并[4,5-d]哒嗪酮基衍生物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11878981B2 (zh) |
EP (1) | EP4323364A1 (zh) |
JP (1) | JP2024511181A (zh) |
CN (1) | CN117545758A (zh) |
TW (1) | TW202309035A (zh) |
WO (1) | WO2022219015A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
CN110225911B (zh) * | 2016-11-28 | 2022-04-05 | 豪夫迈·罗氏有限公司 | 噁二唑酮瞬时受体电位通道抑制剂 |
CN114874209A (zh) * | 2017-03-07 | 2022-08-09 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
-
2022
- 2022-04-13 CN CN202280025202.4A patent/CN117545758A/zh active Pending
- 2022-04-13 WO PCT/EP2022/059818 patent/WO2022219015A1/en active Application Filing
- 2022-04-13 TW TW111113963A patent/TW202309035A/zh unknown
- 2022-04-13 EP EP22722510.9A patent/EP4323364A1/en active Pending
- 2022-04-13 US US17/719,426 patent/US11878981B2/en active Active
- 2022-04-13 JP JP2023558856A patent/JP2024511181A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024511181A (ja) | 2024-03-12 |
TW202309035A (zh) | 2023-03-01 |
EP4323364A1 (en) | 2024-02-21 |
US11878981B2 (en) | 2024-01-23 |
US20220340580A1 (en) | 2022-10-27 |
WO2022219015A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11858921B2 (en) | Uracil derivatives as TRPA1 inhibitors | |
CN115803029A (zh) | 作为trpa1抑制剂的四唑衍生物 | |
US11884681B2 (en) | 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors | |
CN116157130A (zh) | 作为trpa1抑制剂的四唑衍生物 | |
JP2022552520A (ja) | 新規なテトラゾール | |
CN117545758A (zh) | 作为TRPA1抑制剂的咪唑并[4,5-d]哒嗪酮基衍生物 | |
CN114945408B (zh) | 作为trpa1抑制剂的噻吩并嘧啶酮 | |
JP7376706B2 (ja) | Trpa1阻害剤としてのチエノピリミドン | |
US11661427B2 (en) | Tetrazole derivatives as TRPA1 inhibitors | |
US11661430B2 (en) | Tetrazole derivatives as TRPA1 inhibitors | |
CN117222652A (zh) | 作为TRPA1抑制剂的3H,4H‐噻吩并[2,3-d]嘧啶-4-酮衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |